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Multiple sclerosis (MS) is a chronic pathology of the central nervous system, 
characterized by inflammation, demyelination and neurodegeneration. The prevalence 
and incidence rates of MS are on the rise worldwide. What causes MS is unknown. 
However, it is widely accepted that MS occurs in genetically susceptible individuals 
exposed to certain environmental factors. Sero-epidemiological data suggest a strong 
association between Epstein-Barr virus (EBV) and MS. EBV is one of the commonest 
viruses in the human population with ~90% global seropositivity. EBV infects naive 
B cells and immortalizes them. While some postmortem studies have shown EBV in 
MS lesions, others have failed to reach similar observation. Variation in technical 
approaches and sample size could be the reason for reported inconsistencies. Thus, we 
have assessed the hypothesis that EBV may enter MS brain and contribute to disease 
pathogenesis. Four objectives were highlighted in this thesis: to investigate EBV 
presence in MS brain using large sample size, quantify EBV viral load in brain tissues, 
determine possible route of virus entry to the brain, and determine viral gene 
expression in MS brain. In a case-control design, 122 MS and non-MS cases were 
studied and compared. Formalin stored brain coronal slices were received from Rocky 
Mountain MS Centre, US. DNA extraction was optimized and PCR amplification of 
EBV BamHI was performed to determine EBV presence/ absence in the brain. EBV 
viral load was quantified in infected cases using qPCR. Localization of infected cells 
was achieved using EBER in situ hybridization, and viral gene expression was 
determined using immunohistochemistry. The phenotype of EBV infected cells was 
characterized using immunohistochemistry for cellular markers. EBV DNA was 
detected in 90% MS and 24% non-MS cases. EBV infected cells were more prevalent 
in brain parenchyma than in meninges, expressing latent EBNA1 and lytic BZLF1. 
EBV infected cells were likely to have B lymphocyte phenotype. We concluded that 
EBV differential presence in MS brain reflected a pathogenic contribution to MS. 
Further studies are warranted to determine the mechanism of EBV involvement in MS 
pathogenesis. 
 
Keywords: Multiple sclerosis pathogenesis, environmental risk factors, Epstein-Barr 






Title and Abstract (in Arabic) 
 
 دور فيروس ابشتاين بار في التسبب في مرض التصلب المتعدد
 صالملخ
التصلب العصبي المتعدد عبارة عن مرض مزمن يصيب الجهاز العصبي المركزي ويتميز بااللتهاب وضمور 
في طبقة الميالين والتنكس العصبي. معدالت انتشار التصلب العصبي المتعدد في تزايد على مستوى العالم. والسبب 
قابلية الوراثية عن المؤدي الى حدوث المرض غير معروف. اال أنه من المتعارف عليه أنه يحدث في األفراد ذوال
طريق التعرض لبعض العوامل البيئية. تقترح بيانات وبائية مصلية بأن هناك عالقة قوية بين فيروس ابشتاين بار 
% 90الفيروسات الشائعة في اإلنسان، حيث أنه  فيروس ابشتاين بار واحدا من والتصلب العصبي المتعدد. يعد 
من سكان العالم مصابون به. يصيب الفيروس خاليا )ب( ويساعد على بقائها. بينما أظهرت بعض الدراسات 
أخرى أخفقت في  وجود فيروس ابشتاين بار في األعضاء المتضررة بالتصلب العصبي المتعدد، إالّ أّن دراسات
األساليب التقنية وحجم العينة سبب هذه  –من الممكن أن يكون اإلختالف في النهج  الوصول لمالحظات مشابهة.
التناقضات. ولذلك قمنا بتقييم فرضية بأنه من الممكن أن يدخل فيروس ابشتاين بار إلى الدماغ المصاب بالتصلب 
الضوء على أربعة العصبي المتعدد وبالتالي يساهم في تطوير )التسبب لحدوث( المرض. ومن هنا تم تسليط 
أهداف بخصوص هذه األطروحة: التحقق من وجود فيروس ابشتاين بار في الدماغ المصاب بالتصلب العصبي 
المتعدد وذلك باستخدام عينة كبيرة، وإحصاء تجمعات الفيروس في خاليا الدماغ، وتحديد السبل التي من الممكن 
المصاب بالتصلب العصبي  الجينات الفيروسية في الدماغ أن تؤدي الى دخول الفيروس إلى الدماغ، وكذلك تحديد
من الدماغ والتي  ابة بالمرض. وذلك باستخدام شرائححالة مصابة وغير مص 122تمت دراسة ومقارنة  المتعدد.
تم تخزينها في محلول الفورمالين، تم استالمها من مركز روكي ماونتن للتصلب العصبي المتعدد، الواليات 
و تم تنفيذ اختبار تفاعل البلمرة المتسلسل لتحديد وجود الفيروس في الدماغ من عدمه. باإلضافة  ريكية.المتحدة األم
الى إحصاء التجمع الفيروسي من الحاالت المصابة وذلك باستخدام تفاعل البلمرة المتسلسل. ومن ثّم تّم التوصل 
تحديد الجينات الفيروسية عن طريق استخدام  في موقع التهجين، وكما تم EBERإلى الخاليا المصابة باستخدام 
% في الحاالت المصابة بالتصلب العصبي 90و لقد تم اكتشاف الحمض النووي للفيروس في  الكيمياء المناعية.
الدماغ  % في الحاالت الغير مصابة بالمرض. كانت الخاليا المصابة بالفيروس أكثر انتشارا في حمة24المتعدد و 
لقد استخلصنا أن الفيروس الموجود في الخاليا المصابة تعكس مدى مساهمة  في السحايا. هعنه مما كانت علي
 .هناك حاجة للمزيد من الدراسات لتوضيح مدى و كيفية مساهمة الفيروس في المرض. الفيروس في المرض
 
الجينات ر،فيروس ابشتاين با، عوامل الخطر البيئية التصلب العصبي المتعدد،: مفاهيم البحث الرئيسية
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Chapter 1: Introduction 
 
1.1 Overview 
Myelin sheaths are the lipid-rich covers surrounding axons, and formed by 
oligodendrocytes in the central nervous system (CNS), and Schwann cells in the 
peripheral nervous system (PNS). Myelination of nerve fibers has a significant 
importance in speeding up the dissemination of electrical impulse and saving energy 
needed to depolarize axonal membrane during the so-called ‘saltatory conduction’ of 
electrical impulse. Severely injured myelin sheaths can decelerate impulse 
conductance which ultimately can impair affected axonal tracts [1].  
Damage to myelin can be mainly in the form of loss of pre-existing myelin 
(known as demyelination) or deficiency in myelin genesis by precursor cells (known 
as dysmyelination). Demyelination can occur in the CNS and PNS. CNS 
demyelinating diseases arise from a wide array of factors, including ischemic/ hypoxic 
injury, focal compression, viral infection, acquired and inherited metabolic disorders, 
and unusual inflammatory response [2]. The most prevalent demyelinative disease of 
all and the number one cause of neurological (non-traumatic) disability in young adults 
worldwide [2, 3] is multiple sclerosis (MS).  
In MS, prolonged inflammation and extensive loss of myelin around variably 
well-maintained axons disturb the integrity of the white matter in the brain and spinal 
cord. Multiple focal demyelinating lesions, known as plaques, are formed. Plaques are 
an essential characteristic of MS [4]. Plaque activity usually serves as the clinical 
substrate of ostensible disability [5], which varies in magnitude and type between 
patients depending on location, size, number and activity of plaque burden, and CNS 






Fatigue, weakness of limbs, hemiplegia and paraplegia, thermo-sensitivity, 
optic neuritis and partial or total loss of vision, gait problems, ataxia, decreased 
cognitive capacity such as difficulty in recognizing and solving problems and 
decreased information processing skills, are some of the frequent symptoms seen in 
patients with MS [8]. Less common clinical manifestations are seizures and cortical 
deficits such as aphasia, apraxia and agnosia [7] (figure 1.1). Disability resulting from 
disease progression does not directly cause the death of MS patients [9] but MS 
patients carry an elevated risk of all-cause mortality ranging between 1.7 [10] and 3.5 
fold higher than general population [11].  
 
Figure 1.1: Most common symptomology of MS. Data is according to latest update 
of Atlas of MS. Adapted from MSIF, MS Atlas 2013 
Disability caused by MS, in most cases, accumulates, progresses till it reaches 
irreversibility threshold and thus worsening of symptoms, all of which make MS a 
huge socioeconomic burden [12]. Disease symptoms require continuous monitoring 
and management, as more than half of MS patients will need aid with movement in 
about 2 decades after disease onset. The majority of individuals afflicted by MS are of 






distributed in 2003 and 2007, by the Australian Multiple Sclerosis Longitudinal Study 
showed a total 5.4% decrease in part- and full-time employment in the MS population. 
This notable loss of employment was commonly attributed, by respondents, to MS-
related fatigue, difficulty in moving limbs and mobility, cognitive problems such as 
struggle in concentration and remembering tasks, and difficulty in maintaining balance 
of posture. This is one aspect of the impact of MS on the quality of life (socio-
economic status) of MS patients [14]. 
1.2 Clinical Subtypes 
Clinical course of MS follows two distinct phases, the phase of discontinuous 
attacks, known as relapsing-remitting (RR) and the phase of uninterrupted progressive 
deterioration [4]. MS is initiated in the majority (~90%) of patients in the form of 
RRMS [15]. Most patients who are proven to harbor a form of inflammatory CNS 
demyelinating disease after they have undergone CNS diagnostic biopsy are found to 
suffer from RRMS [16]. RRMS usually starts with serious sudden deficit(s) [15] 
persisting from a day to weeks [17, 18]. From this point onwards, the disease course 
becomes unpredictable and patients suffer from uncertainties regarding their fate. No 
single patient suffers the exact same symptoms the same way and the same severity 
for the same period of time as another does. A complete or incomplete recovery 
follows the symptom(s), thus the name relapsing-remitting [6, 19].  
The term clinically isolated syndrome (CIS) is introduced to describe those 
initial MS symptoms that suddenly appear and suddenly go away [18]. CIS can occur 
as a severe acute form of disability or trivial symptoms that some patients may ignore 
to seek medical care for [6]. More than half of CIS patients have white matter lesions 






patients remain clinically silent for 20 years before they become symptomatic resulting 
in either RR course or progressive course [18].   
It takes ~15-25 years for RRMS patients to harbor sufficient irreversible 
damage, and permanent disability with little or no recovery in between manifests [17]. 
This is called secondary progressive (SP) MS [20]. Because SPMS is characterized 
with gradual exacerbation of disability, up to 60% of SPMS patients end up with 
ambulatory hardship, rendering them functionally restricted and unemployed [19].  
In a small subset of patients, MS is initiated with a progressive course, in which 
disease symptoms are continuously worsening from day one of the first attack. There 
is hardly any remissions taking place. This is called primary progressive (PP) MS [19, 
21].  When the progressive course is accompanied by one or more acute relapses, MS 
is called relapsing progressive (RP) [19] (figure 1.2).  
Very rarely, MS disease activity starts with an acute aggressive phase that lasts 
till the death of the patient, within almost a year from disease onset. This defines acute 
MS [21]. 
 
Figure 1.2: Distribution of most prevalent clinical subtypes of MS. Adapted from 







Many of the symptoms experienced by MS patients are non-specific and can 
point to several other possible ailments, such as CNS tumors, systemic vasculitis 
involving the CNS, and hereditary cerebellar ataxia [20]. Therefore, MS diagnosis is 
made upon a combination of clinical and auxiliary para-clinical evidences collectively 
termed the McDonald criteria [6, 20]. McDonald criteria are based on one elementary 
condition that is providing an indication of both temporal and spatial dissemination of 
white matter lesions [22]. Besides MS-suggestive clinical symptoms, radiologic 
evidence, mainly MRI scans, could support MS diagnosis [22]. Although white matter 
abnormalities shown on MRI scans are not disease-specific, MRI has a great sensitivity 
in detecting lesions in up to 95% of MS patients. Demyelination is recognized on MRI 
as small empty bright or dark spots that lie vertically on the axis of the lateral ventricles 
[21]. Specificity of MRI is albeit less than its sensitivity. For instance, the non-specific 
‘normal’ MRI brain lesions appearing after the 5th decade of life can resemble MS 
lesions [20]. Integrating intravenous administration of the heavy metal gadolinium 
(Gd) with MRI scans can reveal focal inflammatory lesions with current activity. 
Active lesions are usually associated with temporarily collapsed blood-brain barrier 
(BBB), which allows the influx of the heavy metal into plaque-affected areas of the 








Figure 1.3: Focal active lesions. MRI scan shows Gd-enhancing lesions suggestive of 
BBB disruption [19] 
Other tests such as evoked potentials in the visual (VEPs), somatosensory and 
auditory pathways and analysis of cerebrospinal fluid (CSF) can also be used in 
diagnosing difficult cases with insidious activity (figure 1.4) [22, 23]. Every 9 out of 
10 MS patients have elevated production of immunoglobulins and multiple distinct 
IgG oligoclonal bands (OCBs) in their CSF [19, 20, 23]. These observations are 







Figure 1.4: McDonald criteria of MS. In RRMS, minimum of two separate evident 
clinical episodes (dissemination in time and space) can, with no additional tests, 
establish the diagnosis of MS (top panel). When only a single clinical event is 
objectively evident, MRI scan showing a Gd-enhancing lesion can be sufficient to 
establish MS diagnosis (middle panel). To establish MS diagnosis in PPMS course, 
persistent clinical symptoms should be confirmed by MRI brain and spinal cord 
lesions together with intrathecal IgG synthesis (IgG OCBs) (bottom panel) [20] 
1.4 Epidemiology of MS 
The foundation of epidemiology of an ailment is that it does not take place 
randomly but in patterns. The observed patterns may, in one way or another, suggest 
the maneuver of the underlying causes, and probably shape the distribution of risk 
factors [24]. The fast accumulating epidemiological studies of MS has formed massive 
repositories of data of MS prevalence and incidence. However, the meta-analytic 






observation differs from one study to another in sample size, age range, ethnicity, 
composition of the sample, and the amount of public awareness of MS as a disease. 
Second, there is an inconsistency between studies in the ability of recognizing and 
including benign MS cases. This may result from the highly variable disease latency 
period at which MS ascertainment could be difficult. Accessibility to appropriate 
medical expertise in MS including MS specialized neurologists, MS diagnostic tools 
and modified criteria and consistency level of interpretation of results obtained from 
MS tests, indirectly impacts incidence rates in a given population [25, 26].  
The fact that MS has a complex component of interactions between genes and 
environment has complicated the epidemiological norms of MS. This has been evident 
in migration studies. Factors, such as distance from the equator (i.e. latitudinal effect), 
ethnicity, and migration from low- to high-risk region during or before adolescence, 
have moulded distribution of MS cases in a unique pattern that is far from being 
globally even (figure 1.5) [27].  
Worldwide, the incidence of MS ranges from 0.5 to 20.6 per 100,000 
individuals annually. This incidence rate has resulted in a prevalence that ranges from 







Figure 1.5: Distribution of MS worldwide. Prevalence rates are according to the 
latest update of reports collected by Multiple Sclerosis International Federation 
(MSIF) [29] 
World Health Organization (WHO) and Multiple Sclerosis International 
Federation (MSIF) put a huge effort in gathering data from 112 countries (~87% of the 
world) (figure 1.5) to update the most comprehensive atlas of MS epidemiological 
parameters in 2013 (mapping Multiple sclerosis around the world). The atlas revealed 
a notable increase in the global prevalence of MS reaching to 2.3 million people, partly 
in response to improved MS-oriented services such as MS-expert neurologists and 
MRI machines that support diagnostic accuracy [29, 30]. The increase in MS burden 
has led to an intense need for searching for causes of the disease and effective therapies 
[31].  
Despite variations in MS distribution between different continents and between 
different regions within one continent [27], MS appears to have a predilection to the 






gradient seems to diffuse in some regions, such as the US, where new patterns of MS 
distribution have been reported [28, 32].  
Although MS prevalence seems to be on rise, it does not accurately reflect the 
level of MS risk. Increased MS prevalence is partly due to the increased life expectancy 
of MS patients due to improved health care services and disease management. 
Therefore, rate of incidence of new cases may be more accurate in reflecting the level 
of MS risk. The incidence of MS is increasing, and in many regions is thought to reflect 
a true increase mainly due to increased incidence in females. Hence, increased female-
to-male sex ratios. In Iran, for instance, this ratio has drastically peaked to 3.12:1 [33]. 
Similar observation has been reported in the US [34]. The most reliable data proving 
such bias comes from the national Danish MS registry [27, 35]. Also, MS prevalence 
and incidence show bias towards certain age groups and ethnicities. In the US, MS 
prevalence peaks in the age category of 45-49 years [34]. A US military study has 
reported higher incidence of MS in blacks compared to whites [28].  
Furthermore, MS distribution is affected by migration patterns. A recent study 
from Norway [36] has showed that Iranian immigrants appear to acquire high MS risk 
that is similar in magnitude to what native Norwegians face, but higher than the risk 
that Iranians face while residing in Iran (country of origin) [36]. This implies the role 
for an environmental component in elevating MS risk. Similarly, higher MS 
prevalence has been noted in second generation Pakistanis compared to their first 
generation immigrants in Norway [36]. These data support the notion that MS risk 
rises when migrating from a low-risk area to a high-risk area [37]. Nonetheless, this 
effect does not seem to apply to certain ethnicities such as Vietnamese immigrants to 






MS epidemiological studies are lacking from the Middle East and North Africa 
(MENA) region. In general, prevalence of MS in MENA countries has been estimated 
to be around 50 per 100,000 individuals (ranging from 14.77 (Kuwait, 2000) to 101.4 
(Turkey, 2006) per 100,000 individuals) [38]. However, these data do not provide 
distinction of MS distribution between Arabs and non-Arab races (such as Berbers, 
Kurds and Black Africans) living in MENA [31]. Available data from Kuwait have 
shown an increasing trend in the incidence of MS [39]. In the UAE, latest data shows 
that MS annual incidence rate has increased to 7 per 100,000 individuals per year [40]. 
Overall, there seems an upward shift in both MS incidence and prevalence in the Gulf 
countries. Studies that monitor and look for reasons for this shift are needed.  
1.5 Pathology of MS Plaques 
Pathologically MS possesses four intermingling aspects, 1) inflammatory 
feature which may or may not be the primary event involving different cellular and 
humoral immune participants, 2) dynamic demyelination of axons, 3) axonal injury 
that is partially resolved by limited CNS repair capacity but eventually progresses to 
varying levels of axonal loss (30-80% loss [41]), and 4) astrogliosis. Each one of these 
aspects can be manifested in the clinical course of MS. For instance, transient BBB 
breakdown and subsequent influx of inflammatory cells into the brain’s active lesion 
link to a new episode of symptoms, while irreversible disability reflects axonal loss 
that is beyond brain’s capacity to repair [42].  
Overall, plaques in MS brain could be very heterogeneous in respect to amount 
of inflammation, expansion of demyelination, capacity to re-myelinate and extent of 
damage to axons. [5]. Formation of focal acute lesions depend on dynamic breakdown 






edematous regions. T cells, monocytes and lipid-laden ‘foamy’ macrophages all 
contribute to peeling myelin off of axons, resulting in apoptosis of oligodendrocytes, 
reactive gliosis, and formation of  perivascular cuffs (inflamed blood vessels) [5].  
As time passes, most of acute plaques turn into chronic well-demarcated 
regions. Immune infiltration subsides in chronic lesions, and myelin loss becomes 
apparent. Accumulation of myelin loss and diminished axons give chronic plaques a 
distinct gross appearance of translucent color-faded areas [5]. Axonal loss can spread 
beyond the borders of MS lesions, reaching to areas known as the normal-appearing 
white matter, and normal appearing gray matter [42].  
Based on histological and immunohistochemical staining, MS white matter 
plaques are differentiated into early and late active lesions, smoldering or slowly 
expanding lesions, inactive lesions, and completely remyelinated lesions (shadow 
plaques). Active lesions have a compact content of macrophages engulfing vacuoles 
of various myelin debris indicating current activity of the lesion. In smoldering lesions, 
the center lacks myelin destruction activity, but surrounded by a fence (rim) of 
activated microglia [3]. Whereas inactive lesions are sharply demarcated areas lacking 
any noticeable activity of myelin degradation. Lastly, remyelinated shadow plaques 
are well-defined areas, marked by substantial fibrillary gliotic scar formation, which 
is histologically revealed by increased staining for GFAP (glial fibrillary acidic 
protein). Fully remyelinated plaques are found to be the most vulnerable sites for 
second episode of myelin destruction [3].  
Although MS definition gives the impression that it is mainly a white matter 
disease, yet the occurrence of diffuse injury in the grey matter is common and can 
happen as early as the onset of first MS attack. Grey matter plaques are frequently seen 






diseases do not show such feature [41]. Unlike white matter lesions, cortical lesions 
do not associate with BBB breakdown or influx of immune cells [41], hence their poor 
detectability in MRI scans [44]. Grey matter damage usually takes the form of 
irreparable extensive loss of neurons [45] and nerve transection resulting in 
neurodegeneration [5]. Clinically this can be translated into irreversible disability [46]. 
Established myelin histochemical stains such as Luxol fast blue (LFB) and oil red O, 
seem to have inadequate sensitivity to reveal grey matter demyelination. In contrast to 
these stains, using myelin basic protein (MBP) immunohistochemistry has been 
relatively successful in showing deep cortical lesions [44]. It has been found that 
subpial cortical lesions are crowned by inflamed meninges that carry several 
aggregates of lymphocytes similar in structure to ectopic B cell follicles. In progressive 
MS, presence of ‘B cell follicle-like’ structures seem to accelerate disease course [5]. 
Meningeal lymphocyte aggregates and CSF are suggested to harbor soluble factors 
that signals pathological events leading to cortical lesion formation [41, 47]. 
1.6 Immunopathogenesis of MS 
 A collection of data from genetic, immunological, and histopathological 
studies strongly support the involvement of the immune system in the pathogenesis of 
MS [41]. The CNS, however, lacks the lymphatic system as we know it, and major 
histocompatibility complex (MHC) class I and class II molecules are far from being 
constitutively expressed by cells in the CNS parenchyma. This, in the past, led to the 
belief that the CNS is excluded from immunosurveillance [48]. The notion of the CNS 
being an immune privileged site has been substituted with a more accurate term 
‘immune specialized site’ to accommodate the highly cautious immune response to 






Under physiological conditions, CSF drain occurs in certain anatomical spaces 
open for immune surveillance by lymphocytes. CSF drain, collected in the 
leptomeningeal space, carries ‘CNS-accessed’ antigens all the way to the cervical 
lymph nodes, where recirculating lymphocytes encounter their antigens [49]. Immune 
surveillance of the CNS is partly regulated by the CSF-producing choroid plexus, a 
highly vascularized element within the ventricles. Choroid plexus is made up of a layer 
of epithelial cells connected by tight junctions on the surface facing the CSF medium. 
This feature qualifies choroid plexus to guard the integrity and enhance protection of 
BBB. The epithelial layer of the choroid plexus surrounds fenestrated blood vessels 
located within choroid plexus parenchyma (figure 1.6), forming blood-CSF barrier (B-
CSF-B). B-CSF-B may be a route for lymphocytes extravasation into the brain [48].  
The established correlation between frequency of (inflammatory) lymphocytes 
within the CSF and lesion load in the MS brain implies a role for B-CSF-B in 
controlling the exchange taking place between the circulation and the CSF. In MS, 
expression of tight junctions between epithelial cells of the choroid plexus is deficient, 







Figure 1.6: Choroid plexus structure in healthy brain and MS. Choroid plexus is 
made up of a stretch of epithelial cells that surround fenestrated blood vessels which 
are located within the parenchyma of choroid plexus. In healthy controls (left 
panel), leukocytes can flow into the parenchyma where they encounter resident 
APC. Regardless of the results of this encounter, leukocytes do not cross through 
the tight junctions of choroid plexus epithelia which serve as a form of BBB by 
developing B-CSF-B. However, this barrier is, somewhat, dysfunctional under 
inflammatory conditions such as MS (right panel) and lymphocytes that may be 
potentially activated, flow into the CSF where a cascade of inflammatory events 
ensue [48] 
On the other hand, the BBB endothelial layer is supported by feet of astrocytes 
(figure 1.7). Astrocytes make cell-to-cell interaction with local roaming microglia, 
other nearby astrocytes, and myelin-generating oligodendrocytes. Under a stressful 
event like MS, astrocytes tend to retract their feet processes from endothelial layer, 
compromising BBB integrity [50]. Moreover, reactive astrocytes in MS maintain 
production of inflammatory cytokines and chemokines, inviting numerous immune 






disruption early in MS or due to some other unidentified pathophysiological alterations 
in astrocytes ambiance [48].  
 
Figure 1.7: Perivascular astrocytes support BBB. They stretch and press their 
endfeet towards BBB endothelial basement membrane which encloses endothelial 
cells and pericytes. Besides this mechanical support to the BBB, astrocytes maintain 
an interaction with adjacent astrocyte and surveilling microglia [51] 
For long time MS has been thought to be orchestrated mainly by CD4+ T cells. 
This notion has been formulated into the mouse model of human MS, namely 
experimental autoimmune encephalomyelitis (EAE), developed through active 
immunization of susceptible animals with an emulsion of CNS homogenate, myelin or 
its derivatives [42], or through adoptive transfer of CD4+ T cells specific to myelin 
antigens [50]. This model has yielded massive amount of information about disease 
pathogenesis especially in terms of the role of different T cell subsets in 
neuroinflammation [52]. Two main subsets of CD4+ T cells are greatly involved in 
promoting inflammation in MS, T helper-1 (Th1) and T helper-17 (Th17) [41].  
A small proportion of CD4+ T cells reactive to myelin auto-antigens is capable 
of escaping deletion during thymic negative selection. These autoreactive CD4+ T cells 






peripheral autoreactive CD4+ T cells is found unaltered during MS disease. As 
opposed to blood of healthy controls, the surviving population of myelin-specific 
CD4+ T cells in MS circulation produces increased levels of pro-inflammatory 
interleukin-17 (IL-17), interferon–gamma (IFN-γ) and granulocyte-macrophage 
colony-stimulating factor (GM-CSF) [53, 54], and appear unaffected by immune 
checkpoints imposed by regulatory T cells (Tregs), which normally down-regulate the 
activity of inflammatory subsets of T cells [48]. In MS lesions and CSF, increased 
proportions of CD4+ T cells and CD8+ T cells are generated by clonal expansion, 
indicating that T cell activity in MS happens in antigen-specific fashion [55]. Self-
antigens that trigger autoimmune response in MS remain largely unidentified [41].  
There is also clonal expansion in B cell population in MS lesions with 
specificity for axonal antigens [50]. The role served by B cells is believed to involve 
antigen processing and presentation, and subsequent release of myelin-reactive 
antibodies [56]. Autoantibodies secreted by plasma cells can bind oligodendrocytes 
and signal complement activation to induce myelin destruction [41]. The large fraction 
of B lymphocytes and plasma cells in MS lesions, meninges and CSF seem sustained 
partly by glia-derived cytokines and endogenous survival signals [12]. 
CNS-resident microglia is another immune cell subset playing a role in MS 
immunopathogenesis. The neuroinflammatory stress taking place in MS lesions 
stimulate activation of microglia. In response to pathological activation, microglia 
multiply with increased expression of MHC molecules, and generate various 
inflammatory cytokines and reactive oxygen species (ROS). They also functionally 
switch into phagocytic cells [50]. Other prevalent innate immune cells are monocyte-
derived macrophages. Together with activated microglia, macrophages can either 






communication with adaptive immune cells. To directly cause tissue injury, microglia 
and macrophages serve as phagocytes that destroy myelin sheaths around axons and 
damage naked axons [57].  
Due to the substantial contribution of the immune system to MS pathogenesis, 
several disease-modifying treatments (DMTs) used in MS are immunosuppressive or 
immunomodulatory. Generally, these treatments are relatively more effective in 
RRMS than in progressive MS. [17, 41]. Some DMTs are of broad action targeting the 
peripheral immune system in general, such as interferon-beta (IFN-β) [41]. But many 
other DMTs target specific components/ molecules involved in the immune response 
cascade. Examples include natalizumab, a blocking monoclonal antibody that binds 
the integrin VLA-4 on the surface of immune cells, so that VCAM-1/VLA-4 
interaction does not take place. The inhibition of such interaction rapidly reduces 
immune cell influx into the brain. Similarly, fingolimod and siponimod inhibit the exit 
and subsequent migration of T lymphocytes from peripheral lymphoid tissues [58, 59]. 
Other monoclonal antibodies, such as anti-CD52 alemtuzumab and anti-CD20 
rituximab, reduce the frequency or efficiency of inflammatory lymphocytes [17]. MS 
patients also now have the option of chemotherapy and subsequent autologous 
haemopoietic stem-cell transplantation. This treatment aims at eliminating 
immunological memory responsible for damaging effects of autoimmune response. 
This could occur through employing immune cells depleted transplant, so that the 
chances of generating self-tolerant immune system are better [60]. 
1.7 Risk Factors for MS 
 What causes MS is not known, however it is widely accepted that there is an 






individuals more susceptible to MS than others [20, 61-64]. The difference in MS 
distribution between individuals from different ethnicities living in the same region 
(i.e. exposed to the same environmental factors) mirrors the influence of genes. 
Whereas the accumulating evidence of increased MS risk in immigrants to high-risk 
area compared to the general population in the country of origin denotes the impact of 
the complex interaction between genes and environmental factors on MS risk [36].  
1.7.1 Age 
 The pattern of MS occurrence has made MS a disease of the youth. The 
incidence of MS peaks between the second and fourth decade of age, while pediatric 
onset of MS [65] and MS starting in advanced age are relatively less common. This 
makes age an important risk factor for MS [66].  
1.7.2 Genetics 
Susceptibility to MS is highest in Caucasians of northern European origin, 
particularly in those originating from Scandinavia and Scotland, and lowest in 
Chinese, Japanese, Samis, Uzbeks, Kazakhs, Gypsies, Eskimos, indigenous peoples of 
the Americas, and Indigenous Australians [67]. To a modest degree, MS is heritable 
among those who demonstrate increased genetic sharing. MS risk probability is about 
1 in 40 when a parent or a sibling has MS. While there is 2-5% MS risk when one of 
the same-sex fraternal twin has MS, if one of monozygotic twin has MS, the other twin 
has 25-30% MS risk. Also, studies in half siblings and adoptees confirm the genetic 







Figure 1.8: MS risk according to percentage of gentic sharing. Increased 
concordance in monozygotic compared to dizygotic twins. When both parents are 
affect by MS, their offsprings are at higher risk of developing MS than those with 
only one affected parent. MS risk is almost 2 times less in half-siblings than in full 
siblings. Adoptees who share no genetic background with the raising family face 
almost the same MS risk that the general population do [20] 
Multiple genes are found to impact susceptibility to MS. Repeatedly confirmed 
reports point to the involvement of immune-associated HLA class II locus on 
chromosome 6p21.3; linked to HLA-DR2 haplotype [64]. This locus is believed to be 
accountable for 20-60% risk of developing MS [64]. For example, carrying 
HLADRB1*1501 genotype together with  infectious mononucleosis (IM) history 
increases MS risk to 7 folds, compared to less than 3-fold increase associated with 
carrying HLADRB1*1501 alone [68]. Beside HLA class II region, HLA class I locus 
has also been linked to MS risk. Susceptibility to developing MS and the risk of 
acquiring IM seem to overlap in a region in HLA class I locus [68]. Furthermore, 
several other non-HLA gene loci have been associated with MS risk, they appear to 






associated with regulating immune system response [61]. Some of the allelic variants 
reported to be in association with increased MS risk seem to confer protective trait 
against other autoimmune disorders indicating the complex link between 
autoimmunity and autoimmune-related allelic variants [64, 69, 70]. 
1.7.3 Gender 
As the case with numerous autoimmune disorders, MS occurrence has a 
predilection for females. Female-to-male ratios of MS incidence has risen to reach 3:1 
[66, 71-74]. This widespread consistency of biased female-to-male ratios suggests the 
influence of sex hormones on susceptibility to MS. Thus, such demographic 
distribution has necessitated stratification for gender in MS studies [75].  
It has been suggested that the rising trend of decreased menarcheal age may be 
one reason for increased female MS incidence. The interplay between age at menarche 
and MS risk-related genotype may pave the way for early (adolescent) onset of MS 
[76]. Also, the prevalence of HLA DRB1*1501 is found higher in female MS patients 
than in their male counterparts [75]. 
1.7.4 Environmental factors 
 Epidemiological data indicate the involvement of environmental factors that 
interact with genetic factors to shape immune response in developing MS [41, 77]. 
Immigration studies reveal changes (decrease or increase) in MS risk that has been 
taking place within one-generation time. This is too little time for genes alone to cause 
such changes [61].  Many environmental factors have been studied in association with 






1.7.4.1 Sunlight and vitamin D 
The involvement of ultraviolet (UV) light in determining MS risk came from 
studies comparing duration of sun exposure in individuals who have developed MS 
and in healthy controls, and the finding that UV-induced skin cancers are uncommon 
in MS patients. On the molecular level, UV light shifts the immune reaction away from 
Th1 cell response. But how much exposure to UV really contributes to protection from 
MS is unclear given that MS prevalence is at the low side in MENA region, where 
most people dress in conserved (skin-covering and UV-blocking) clothing. This 
suggests that sun exposure on its own has little effect on MS risk. This factor rather 
appears to interact with other genetic and environmental factors in ways to be 
illustrated [79]. Effect of low sunlight exposure in increasing MS risk has been found 
more pronounced in females than in age-matched males [80].  
Within the same context, impact of serum levels of vitamin D on MS risk has 
been studied extensively, alone and in association with other environmental factors 
such as UV exposure and latitudinal effect [81]. It has been suggested that high serum 
level of vitamin D is a protective factor against MS. Although debatable, vitamin D 
supplementation has been linked to reduced MS symptoms. It is thought to happen due 
to immunoregulatory functions served by vitamin D, including attenuating release of 
inflammatory cytokines. Moreover, a link between polymorphisms taking place in 
vitamin D receptor gene, vitamin D metabolism and MS risk has been considered [82-
84].  
1.7.4.2 Obesity 
Obesity is another risk factor reported in association with MS development. A 






to more than 2 folds in obese (body mass index ≥30 kg/m2) individuals. The effect of 
obesity seems to influence susceptibility to MS mainly during adolescence [85]. 
Increased overall body fat is frequently accompanied by low levels of circulating 
vitamin D, as this water-insoluble vitamin tends to get trapped within adipose tissue. 
Thus, obesity may increase MS risk partly through causing a decline in levels of the 
immune regulatory vitamin D [86]. Moreover, fat cells release inflammatory cytokines 
providing a source of inflammation [85, 87]. Obesity is believed to interact with MS 
risk-associated HLADRB1*1501 causing elevated probability of developing MS [87, 
88]. Obesity may also interact with several other factors, including female sex, 
adolescence age and black race, to increase susceptibility to MS [89].  
1.7.4.3 Smoking 
Smoking has been associated with increased MS risk in many studies [90-93]. 
It has been estimated that smoking contributes to 30-40% mean rise in MS risk. This 
effect appears more pronounced in females than males [90]. Neurotoxicity, disrupted 
immune regulation, general toxicity induced by chemical ingredients and byproducts 
of tobacco [90] and triggering upper respiratory tract infections [92] are some of the 
means postulated to explain effect of smoking on susceptibility to MS [90]. Although 
smoking increases susceptibility to MS in both genetically- and non-genetically-
susceptible individuals, the magnitude of MS risk differs between the two groups. 
Smokers positive for HLADRB1*1501 are shown to face a 14-fold rise in MS risk [94]. 
There are other environmental factors that lack consistency in their link to MS 
risk including educational background and socioeconomic status, exposure to high 
levels of stress [95], month of birth [96], geomagnetic instability (disrupted 






such as diary workers in the agricultural field [98], history of migraine [99], growing 
up with siblings or going to a day-care center during early years of life, gut’s normal 
flora [100] and having asthma [101]. Also because MS occurs spontaneously only in 
humans and not in other non-human primates, some have argued for the association of 
certain ‘human-specific’ elements in MS risk [102].   
Overall, more than 40 environmental risk factors have been studied in 
association with MS. Nonetheless, there is null association between the majority of 
these factors and MS. According to Belbasis and co-authors’ umbrella review [103] 
only three environmental factors appear strongly associated with MS, smoking, 
Epstein Barr virus (EBV) and history of IM [103]. 
1.7.4.4 Infectious agents 
Few incidents, such as MS outbreak in Faroe Island during World War II, and 
few reports of MS incidence in clustering fashion (e.g. familial clustering of MS) 
indicate the involvement of an infectious agent in establishing MS risk [61]. To explain 
the involvement of infectious agents in the pathogenesis of MS, the hygiene hypothesis 
has been introduced [104]. The hypothesis postulates that a number of unidentified 
infections occurring during early years of life prevents development of MS later in 
adulthood. Whereas exposure to these infections at advanced age in genetically 
susceptible individuals predispose them to increased risk of developing MS [105]. The 
hygiene hypothesis successfully answers certain aspects of MS geographical 
distribution [106]. MS prevalence is low in tropical regions, where various bacterial, 
viral and parasitic infections are endemic. This increases the chance of acquiring 
infections as early as first year in life [107]. Similarly, MS risk is lower in individuals 






microorganisms [108]. A stable rise in MS incidence has been observed in low-income 
regions over the past 30 years [109]. Within the same period of time, these regions 
witnessed a decline in frequency of infections as a result of advances in infection 
control, better access to healthcare units and medical interventions (vaccines, 
antibiotic, and enhanced sanitary conditions) [110]. The epidemiological linkage 
between the two observed trends support the hygiene hypothesis [111]. However, 
hygiene hypothesis falls short in explaining some epidemiological observations 
including that the risk of developing MS in individuals who have never been exposed 
to EBV is 10 fold lower relative to those who were exposed to asymptomatic early-
life EBV infection [108].  
A wide range of infectious agents has been suggested to play a role in altering 
MS risk, as either protective [112] or MS conferring factors, in genetically susceptible 
individuals, when happening during specific life age [111]. For example, it has been 
suggested that helminth infections may be protective against MS [113, 114]. Similarly, 
clinical history of chickenpox (varicella zoster virus (VZV) infection) [115] and 
cytomegalovirus (CMV) infection [116] are reported to reduce risk of adolescence 
onset of MS. Moreover, it is believed that Helicobacter pylori infection exerts 
immunomodulatory effects through antigens that can shift cell-mediated response 
from the inflammatory Th1 subset to anti-inflammatory Th2 subset, thus decreases the 
likelihood of developing autoimmune response associated with MS [117, 118]. On the 
other hand, Mycobacterium Avium Subspecies Paratubercolosis (MAP) infection is 
thought to promote MS risk in genetically predisposed populations such as Sardinians, 
probably as a result of cross reactivity [119, 120]. Human herpesvirus 6 (HHV-6) has 






Additionally, MS association with differential expression of human 
endogenous retroviruses (HERVs) has been frequently reported [125-127]. 
Retroviruses are distinct in their capacity to make an intimate connection with host 
DNA in a process called integration. In more precise terms, HERVs are retroviral 
insertions into the human genome following infecting germ-line cells long time ago. 
Since then, HERVs have been vertically transmitted from one generation to the next, 
and now represent about 8% of our genome [128-131].  
While the literature is rich with lists of infectious agents possibly associated 
with MS [111, 122, 132-135], notably abundant evidence from sero-epidemiological 
data and meta-analysis studies strongly highlight the role for EBV in MS pathogenesis. 
In fact a recent umbrella review has reported that over 50% of meta-analyses 
conducted on EBV association with MS had significant p values [103]. 
1.8 Epstein Barr Virus (EBV) 
1.8.1 Herpesviridae  
EBV is a member in the Herpesviridae [136], a large family that encompasses 
over hundred identified DNA viruses [137]. Herpesviridae contains eight important 
viruses, which infect only humans and belong to 3 subfamilies. Alphaherpesvirinae 
covers herpes simplex virus type 1 and 2 (HSV-1 and -2), and varicella–zoster virus 
(VZV), while Betaherpesvirinae includes human cytomegalovirus (CMV), human 
herpesvirus 6 (HHV-6), and human herpesvirus 7 (HHV-7), and lastly, 
Gammaherpesvirinae contains EBV and Kaposi's sarcoma herpesvirus (KSHV) [136, 
137]. Characteristically, herpesviruses possess the capacity to persist in latent form 
within particular tissues toward which these viruses show tropism. The latency persists 






gene expression is barely traceable under normal physiological settings. Yet, nucleic 
acids of herpesviruses can be readily detected  [137]. Overall, herpesviruses own a 
characteristic structure consisting of four main components, DNA core encircled by 
an icosahedral capsid, tegument, and lipid bilayer envelope [136, 137].  
Herpesviruses DNA is unique in its sequence arrangement, and based on this 
feature herpesviruses are categorized in A to F groups. Groups C to E contain the eight 
human herpesviruses. The genome of group C herpesviruses contains a number of 
well-characterized domains divided by several terminal repeats. EBV and KSHV 
belong to group C. The genome of group D forms two equivalent molar sets as a result 
of sequences from one terminal region being reiterated internally but in reverse 
direction. VZV fits in group D. Lastly, the unique distribution of sequences within 
genome of group E is arranged by internal reiteration of both terminal sequences in 
opposite direction generating four equal molar sets. HSV and CMV are members of 
group D [137]. 
Compared to other subfamilies, gammaherpesviruses are tropic toward limited 
host range. In vitro, gammaherpesviruses replication takes place inside lymphoblastoid 
cells, with a capacity to cause lytic infection in some cells. Latent infection is well-
established in lymphoid tissues [137]. Gammaherpesviruses contain two genera, 
Lymphocryptovirus (LCV; gamma 1) genus and Rhadinovirus (RDV; gamma 2) genus 
[138]. 
1.8.2 Biology of EBV (human herpesvirus 4: HHV-4) 
In 1964 Epstein’s laboratory was successful in detecting –using electron 
microscopy- and isolating the first human oncogenic virus from Burkitt’s lymphoma 






constitutes a fundamental part of human existence, because infected individuals are 
persistently infected with EBV and more than 90 % of adults are EBV carriers [140]. 
Despite this high prevalence of EBV in the human population, occurrence of serious 
EBV-related illnesses in most infected individuals is rare. Recent studies indicate that 
EBV- associated cancers account for approximately 1.8% of all cancer-related 
mortality worldwide [141]. This percentage, also, seems to be on the rise. Thus, the 
overall EBV infection burden takes a toll on human population [141, 142]. 
Two types of EBV are known to infect humans, EBV-1 or –A and EBV-2 or –
B [143]. Geographically, EBV-1 is dominant in developed countries, while EBV-2 is 
frequently circulating in Sub-Saharan Africa. The division of EBV into two types has 
emerged based on genetic variation observed in the sequence of genes encoding EBV 
nuclear antigens, namely EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C and EBNA-
leader protein (EBNA-LP). Sequence variation between the two EBV types in primary 
amino acids within EBNAs alleles ranges between 47% and 16% [138]. Furthermore, 
each EBV type is sub-divided into strains, depending on variation in EBV DNA 
repeats. Equal repeats in EBV DNA between EBV isolates from a population help sort 
isolates into strains thus feasible tracking of EBV infection [138].  In vitro, EBV-1 
shows better efficiency in immortalizing B lymphocytes than EBV-2. This is probably 
due to sequence variations in EBNA-2. Also, lymphoblastoid cell lines (LCLs) have 
better viability when infected with EBV-1 than with EBV-2 [144]. 
EBV possesses similar architecture of virus structure of that of other 
herpesviruses. EBV capsid is made up of the following: major capsid protein (the 
biggest among capsid proteins), minor capsid protein, minor capsid protein-binding 
protein, small capsid protein, and portal protein. The protein tegument consists of viral 






proteins), large tegument protein-binding protein (BOLF1), major tegument protein 
(BNRF1), myristylated protein (BBLF1), myristylated protein-binding protein 
(BGLF2), palmitylated protein (BSRF1), capsid-associated protein (BVRF1), 
packaging protein (BGLF1) and serine-threonine protein kinase (BGLF4). The cellular 
proteins making up the tegument include actin, beta-tubulin, enolase, cofilin, and heat 
shock proteins 70 and 90. The virus-encoded glycoproteins (gps) of the envelope 
comprise gp350 (BLLF1), gp150 (BDLF3), gp78 (BILF2), gp42 (BZLF2), gB 
(BALF4), gH (BXLF2), gM (BBRF3) and gN (BLRF1) [138]. 
1.8.3 Structure of EBV genome 
A linear dsDNA molecule makes up EBV’s ~172 kb genome. EBV genome is 
divided into short (US) and long (UL) largely unique regions, on which EBV genome 
coding capacity heavily rely (figure 1.9). This division results from occurrence of 2-5 
tandem, 0.5 kb direct repeats carrying the same sequence at both terminals (terminal 
repeats; TRs) in addition to 6-12 tandem, 3 kb internal direct repeats (IRs). Open 
reading frames (ORFs) of EBV genome carry much of perfect and imperfect tandem 
repeats, IR2 and IR4. Close to the left end of UL region is IR2, which is homologous 
to and mirrored in near to right end of UL with IR4. IR2 region covers several tandem 
repeats of 125 bp which are rich in G-C content and greatly conserved sequences. Next 
to these tandem repeats is 2 kb unique DNA. Similarly, IR4 contains high G-C content 
tandem repeats of 102 bp followed by 1 kb unique DNA [145]. Both IR2 and IR4 
contain the origins for initiation of replication of EBV DNA. Tandem perfect repeats 
of EBV DNA are reiterated during DNA replication in varying frequency [138]. 
EBV DNA forms an episome during the event of EBV infecting a cell [146]. 






cleavage and assembly, and number of starting TRs within parent DNA. During EBV 
latent infection, viral episome will contain a number of TRs identical to the parent’s 
episome [147]. Thus, identical number of TRs within episomes in a population of 
infected cells points to one common parent infected cell. Whereas variation in the 
number of TRs indicates multiple cellular sources of infection. Other repeats in EBV 
genome may also vary during viral replication, but they are less indicative of 
heterogeneity due to either small size of the repeats or low frequency of reiteration 
[147]. 
 
Figure 1.9: Structure of EBV linear DNA.  (a) U1 is the short unique sequence and 
U2 is the long unique sequence of EBV genome. U1 and U2 are divided by internal 
repeats (IRs).  Ori-P (grey-shaded circle): origin for EBV episome replication and 
maintenance during latent infection. Ori-lyt (black-shaded circles located right to IR2 
and IR4), origins for genome replication during lytic infection. Location of EBV 
latent genes (on EcoRI and BamHI restriction linearized map) also shown [148] 
ORFs in EBV genome are named after the BamHI-restriction fragment where 
they are located [149]. Most of these ORFs are divided into latent (figure 1.10) and 
lytic genes. Lytic genes include immediate early genes [150], early genes, and late 
genes. Some of the lytic genes are translated into proteins that serve functions 
analogous to certain human cellular proteins [144].  
In vitro EBV infection of B lymphocytes leads to latent infection causing B 
cells to be immortalized [151]. In these cells, up to 11 latent EBV genes are expressed. 
Culturing peripheral blood lymphocytes isolated from EBV carriers under 






outgrowth of EBV infected cells and the establishment of LCLs. Also, EBV isolated 
from EBV positive cell lines can be used to directly infect resting B cells and produce 
LCLs [152]. 
 
Figure 1.10: Position of latent genes on EBV episome  [153] 
In LCLs, several copies of EBV episome can be found in a single cell [153]. 
About 80 genes are encoded by EBV genome, but only a limited number has been 
characterized and detected [138]. Latent proteins expressed in LCLs include six EBV 
nuclear antigens EBNA-1, -2, -3A, -3B, -3C and –LP, and three integral latent 
membrane proteins, LMP-1, -2A and -2B. Each one of the 6 EBNAs is encoded by 
one distinct mRNA. Either Cp or Wp promoters (positioned in BamHI C and W region) 
expresses a “rightward” key transcript that is more than 100 kb long. The differential 
splicing of this transcript produces the different EBNA mRNAs. During early stages 






Different promoters located in the BamHI N region express LMP transcripts. LMP 
promoters are transactivated by EBNA2 [154].  
The function of latent gene products appear to affect differentiation and 
proliferation of host cells, providing EBV with the potential of cellular transformation 
[155]. Most, but not all, of the latent genes are translated into functional protein 
products. For example, EBV-encoded RNAs, EBER-1 and -2 are small non-
polyadenylated, non-coding RNAs expressed in high numbers (estimated at 107 copies 
per infected cell) in all forms of latency [154]. This feature makes EBERs an ideal 
target for the detection of  EBV using in situ hybridization [156]. The viral genes 
expressed in LCLs is a characteristic of latency III (all recognized EBV latent genes 
are expressed). This form of latency has also been noted in some EBV-associated 
conditions, such as post-transplant lymphoproliferative disorder (PTLD), EBV-
infectious mononucleosis (IM), and AIDS-related lymphomas. In addition to type III 
latency, 3 other patterns of EBV latent gene expression have been described [157] 
(table 1.1). In the peripheral compartment of healthy immunocompetent EBV carriers 
who have 1-50 infected B cells per 106 cells [158], the expression of almost all (except 
EBERs [159] and probably LMP2A [160]) viral genes is silenced in non-dividing B 
cells. This is defined as Latency program 0. In latency I program, represented by 
Burkitt lymphoma, EBNA1 is the only viral gene expressed. In latency II program, the 
two LMPs 1 and 2 plus EBNA1 are expressed, as seen in non-differentiated 
nasopharyngeal carcinoma (NPC), EBV-associated Hodgkin lymphoma (HL) and T 









LATENCY PROGRAM EBERS EBNA1 LMP-1, -2 EBNA-2,-3,-LP 
LATENCY 0 + - - - 
LATENCY I + + - - 
LATENCY II + + + - 
LATENCY III + + + + 
 
Table 1.1: EBV Gene expression profile. Different genes are expressed during 
different latency programs [162] 
1.8.4 Epidemiology of EBV infection  
Herpesviruses are ubiquitous in human and non-human primates, and are 
species specific [144]. Despite some recent attempts to deliberately establish EBV 
infection in non-human primates [163], spontaneous EBV infection only occurs in 
humans [164]. With almost universal EBV seropositivity, the virus in the majority of 
the cases remains within the host without producing disease. Primary EBV infection 
frequently takes place during early childhood (first 2-4 years) [165] or even during 
infancy in some developing countries. Early EBV infection is widespread in 
developing countries and does not usually present with clinical symptoms (figure 1.11) 
[166, 167].  
 
Figure 1.11: Age at EBV infection. Data represent 75% of the population in different 






However, primary EBV infection in developed countries tends to occur much 
later, sometimes being delayed until adolescence or early adulthood. Such delayed 
seroconversion is accompanied in 25%-70% of the cases with self-limiting 
lymphoproliferative condition, referred to as infectious mononucleosis (IM) [165, 
168]. 
Oropharyngeal secretion is the main source of EBV transmission. Close 
contact with infected person’s saliva, where active shedding of EBV particles may 
occur, leads to EBV horizontal transmission [169, 170]. Close contact between parents 
and their infants may coincide with active shedding of the virus in the parent’s oral 
cavity, increasing chances of acquiring EBV infection early in life [164]. Also, young 
children may get infected through usual childhood acts of chewing toys that may be 
contaminated or sharing utensils [153]. While the increased infection rate later in 
adolescence and early adulthood is commonly due to kissing an EBV infected 
individual who is shedding the virus [169]. All EBV infected persons shed EBV 
virions in their saliva secretions at varying levels [138]. Accurate correlation between 
the frequency of EBV shedding in saliva and peripheral viral load is poorly defined. 
Thus, conditions promoting viral reactivation in the saliva may differ from that in the 
peripheral blood [171]. EBV can be asymptomatically released in respiratory 
secretions months post-infection and excretion can be intermittent during the life time 
of the host [164, 169]. But so far exact periods of viral transmission are not known 
[164].  
EBV infection rate appears to adopt a bimodality in certain industrialized 
populations, where increased rate of infection is seen during the first 4 years of life 






in EBV infected carriers are peaked during early childhood, likely reflecting primary 
infection, and during late adulthood at which probable virus reactivation can occur 
[172]. Decreased efficiency of the immune system in advanced age may contribute to 
EBV reactivation [169].  
 
Figure 1.12: Frequency of EBV seropositivity. Data represent four different 
geographic populations [169] 
EBV transmission can also occur via blood transfusion [173] and organ 
transplantation settings [164, 174]. On an average estimate, a single unit of 
erythrocytes has two EBV genomes, whereas 600-700 viral genomes can be carried 
within a whole blood unit [175-177]. Blood transfusion in organ transplant recipients 
carries the risk of developing PTLD [174]. Evidence for transmission of EBV through 
transplacental route and sexual contact is limited [169].  
Geographically, two EBV types, described earlier, are circulating in the human 






gene is believed to be geographic area dependent. Polymorphisms in LMP-1 may 
associate with incidence pattern of NPC particularly in isolates from endemic 
populations [179, 180]. 
Similar to other childhood infections, the incidence of early EBV infection is 
higher in populations with low socioeconomic status than in high socioeconomic 
populations where delayed infection is primarily seen. Low socioeconomic status is 
associated with congested living conditions, increased population density within a 
given geographic area, poor hygienic standards and certain socio-cultural norms. In 
these environments where the likelihood of early exposure to various infections is 
increased, EBV seropositivity in young children is high [169]. 
Genetic and Gender-specific differences in EBV distribution are generally 
absent. However, delayed primary EBV infection that is often associated with IM 
symptomology is seen earlier and more frequently in females than in males [181]. 
Compared to their male counterparts, anti-EBV titers tend to be higher in females, who 
are believed to mount stronger response from EBV-recognizing immune cells and 
antibodies. Moreover, no genetic resistance to EBV infection has been reported, but 
host genetics-dependent immune response to EBV may contribute to EBV-arising 
diseases in some individuals but not in others [181].  
1.8.5 EBV load in healthy carriers 
EBV establishes a lifelong latent persistence in B lymphocytes, and latently 
infected cells can be triggered to proliferate [164, 169, 170]. A transient increase in 
peripheral EBV viral load occurs in primary infection, and thereafter declines to stable 
levels that are below 100 copies per µg DNA [182, 183]. EBV resides in resting 






that have undergone isotype-switch and somatic hypermutation [184]. Similar 
frequency of EBV infected cells is seen in different body sites (blood, adenoids, and 
tonsils), except for spleen and mesenteric lymph nodes where the level is 20 fold lesser 
[185].  
In African children residing in regions endemic for malaria, peripheral EBV 
load is as high as that seen in IM patients [186]. EBV viral load differs between healthy 
carriers, but within one person at a given point of time the load is more or less stable 
[158, 187]. Nonetheless, healthy carriers experience raised viral loads at different 
points of time indicating a transient viral reactivation that is soon tackled by a 
competent immune system. The fluctuation of EBV levels can be determined in 
PBMCs and plasma samples, with serum being the commonly preferred sample to use 
for the consistency and reproducibility of measurements. Unlike NPC and PTLD 
patients, EBV levels in plasma/serum can seldom be detected in healthy carriers, but 
viremia can occur during viral reactivation periods [169].  
In blood of healthy carriers, detection of transcripts for LMP2 and EBNA1 has 
been seen, but generally peripheral EBV infected cells have latency 0 as described 
earlier [188, 189]. In contrast to the blood, EBV infected cells in spleen and tonsil have 
been reported to express latency program II [190]. In the tonsils, EBV infected cells 
that may pass through the germinal center have been shown to express CD10. Within 
tonsillar tissue, EBV infected cells can differentiate into plasma cells, and 
transactivation of BZLF1 promoter triggers the beginning of viral productive (lytic) 
cycle [151, 185]. 
Finally, equal EBV load and similar frequency of EBV latent antigens- specific 






lymphocytes reactive against EBV lytic genes appear 3 fold higher in the bone marrow 
compared to that in the blood [138]. 
1.8.6 Dynamics of primary EBV infection 
The oropharynx is the site where EBV infection starts, with viral gp350/220 
binding to resting B cell surface CD21. While gp350/220 is EBV viral envelope 
glycoprotein [191], CD21 or complement receptor 2 (CR2) is a receptor for C3d 
complement molecule [192-194]. CD21 is expressed on B cells and possibly epithelial 
cells of the tonsils [195-198]. This brief interaction between gp350/220 and CD21 is 
followed by endocytosis. EBV lipid bilayer envelope fuses with B cell membrane with 
the aid of EBV glycoproteins, gp42 which interacts with MHC class II molecules, gB 
and gH/gL. EBV infecting epithelial cells has also been reported [199], with viral 
BMRF2 interacting with epithelial surface integrins [138, 200, 201].  
Next at the cellular level, replication and EBV shedding is initiated within the 
oral cavity causing lysis of some infected squamous epithelial cells [202, 203] and B 
lymphocytes. EBV then induces the expression of the full set of viral latent proteins in 
infected B cells in the tonsils (latency III program). Through this growth-transforming 
events, EBV infection spreads. Soon after that, competent cell-mediated immunity, 
particularly anti-EBV CD8+ cytotoxic T lymphocytes (CTLs) [204, 205] and NK cells 
of the innate system, is initiated. This immune response causes EBV to down-regulate 
viral antigen expression [206], thus, growth-transforming program subsides. 
Subsequently few infected cells make up infected memory B cell pool [207]. Lifelong 
latent persistence is established in these memory B cells expressing latency 0 
phenotype. These resting memory cells, as part of normal B cell life cycle, can travel 






[208]. Occasionally, viral reactivation occurs in a portion of these cells [209], which 
are successfully recognized and removed by EBV-specific CTLs. Also, few cells 
sporadically enter the lytic cycle in the oropharynx. New viral particles are produced 
and shed intermittently in saliva at low levels. Viral transmission, then, can occur and 
the ‘life cycle’ of EBV continues in a new host (figure 1.13) [169, 210, 211].  
 
Figure 1.13: EBV infection in an immunocompetent host. Comparison of events 
occurring in EBV symptomatic and asymptomatic infection [210] 
1.8.7 EBV and human diseases 
Viremia, caused during EBV primary infection, triggers a response primarily 
from NK cells and T lymphocytes (figure 1.14) [170]. Unlike IM, asymptomatic EBV 
infection is believed to lack lymphocytosis and oligoclonality of antiviral CD8+ T 
cells, in spite of initial viremia. In fact, the frequency of activated EBV-reactive CD8+ 
T cells reaches up to 18% of peripheral CD8+ T cell pool without marked increase in 






expanded [212, 213]. An association between genetic variation in genes encoding 
immune system components and development of serious EBV infection has been made 
[210].   
 
Figure 1.14: Anti-EBV immunity. Different gene products during EBV latent 
infection and lytic replication (in differentiated plasma cells) are targeted mainly by 
anti-viral CTLs and NK cells, respectively. Note that during early lytic cycle, MHC-
class I- bound lytic antigens (BZLF1, BRLF1, BMRF1 and BMLF1) can efficiently 
trigger a CD8+ T cells response. Whereas during late lytic cycle poor expression of 
MHC class I molecules is compensated with increased expression of NK- 
recognizable NKG2D ligands (NKG2D-L). This phenotypic feature of infected cells 
undergoing late lytic cycle makes them a target for NK cells [214] 
EBV biology and latent persistence are heavily dependent on the virus-host 
immunosurveillance equilibrium (figure 1.14) [160, 214]. Deficient immune 
surveillance, such as in primary (congenital) immune deficiency, can disturb 
(otherwise stable) EBV-host relationship. This is the case in X-linked 
lymphoproliferative syndrome where immune functions, served by T lymphocytes and 






virus-host homeostasis is strongly supported by EBV- related lymphoproliferative 
diseases in immunosuppressed PTLD and immunodeficient AIDS patients [153, 205, 
218-221].  
The role of EBV infection in cancer is well-documented. Annually, about 
200,000 EBV-related malignant cases take place, and EBV now contributes to 1-2% 
of cancer burden worldwide [210, 214]. Some of EBV tumors are preferentially 
prevalent in certain ethnicities, occurring in immunocompetent individuals. The list of 
such tumors includes NPC [222], BL [223], HL [224], and extranodal NK/T-cell 
lymphoma of the nasal type [225].  The pathogenic role played by EBV as an 
oncogenic virus in human malignancies has been studied extensively [226], and details 
of EBV oncogenicity is beyond the scope of this thesis. Besides IM, EBV can cause 
other diseases in immunocompetent hosts including IM-like chronic active EBV 
infection [227], and probably autoimmunity [228-231].    
Role of EBV in autoimmunity is debatable, and virus carriership is thought to 
partly contribute to development of exaggerated immune response against self-
antigens [232]. EBV has been linked to a number of autoimmune diseases such as 
systemic lupus erythematosus and rheumatoid arthritis [232]. An accumulating body 
of evidence suggests that EBV may also be involved in the pathogenesis of MS.  
1.8.8 Available data for an association between MS and EBV  
Data from epidemiological, serological, in vitro, and postmortem studies 
support a role for EBV in MS pathogenesis. First evidence comes from identical 
geographic distribution of IM (caused by EBV) and MS [233]. IM has also been 
suggested as a strong risk factor for MS [234]. Reporting a history of IM increases the 






be needed to direct the immune system toward an exaggerated response as seen in MS 
[236]. Moreover, IM is believed to increase the risk of MS for 30 years post EBV 
infection [237].  
Another indicative observation of EBV contribution to MS is that almost all 
MS patients are EBV seropositive compared to 90% of the global population [233]. 
This is consistent with the findings that the odds ratio of developing MS is higher in 
EBV-seropositive persons than that in non-infected individuals (13.5 vs 0.06 
respectively). However, the risk of MS rises in those EBV-seronegative individuals 
soon after they seroconvert [232]. EBV seropositivity is also higher in pediatric MS 
patients compared to their matched controls (83% vs 42% respectively) [238].  
Comparing humoral response directed to EBV antigens, in the peripheral 
and/or intrathecal compartment, between MS patients and their matched heathy 
controls is another approach used to investigate potential relationship between the 
virus and MS. Although no association between MS risk and EBV viral load exists, 
MS risk is found linked to serum levels of anti-viral capsid antigen (VCA) and anti-
EBNA1 IgG antibodies [239]. Elevated antibody index directed against EBNA1 
antigen in the blood tends to occur before the onset of MS [240], and thus these 
antibodies may be a predictive marker for MS [241].  
In relation to MS risk, there seems an overall triangle of links joining (a) history 
of IM and anti-EBNA1 IgG titers, (b) history of IM and genotype of HLA DRB1*1501, 
and (c) titers of EBV- specific antibodies and HLA DRB1*1501. It has been indicated 
that both elevated titers of anti-EBNA1 antibodies and carrying HLA DRB1*1501 
raises the risk of developing MS [233]. Whereas some believe that each of these two 
factors operate independently towards MS risk [242], others suggest that circulating 






pathways in which HLA molecules impact the risk of developing MS and immune 
regulation of a lifelong EBV infection. In other words, elevated risk of MS is conferred 
to individuals carrying increased load of anti-EBNA1 IgG and at the same time are 
positive risk allele HLA DRB1*1501. The increased index of antibodies specific to 
epitopes derived from EBNA1: 385–420 domain is particularly of great importance in 
MS risk [243]. This domain carries sequences homologous to anti-inflammatory α-b-
crystallin, to which amplified T cells respond in MS. Thus, it is possible that enriched 
peripheral humoral response to specific EBNA1 domain breaks immune self-tolerance 
and aggravates autoimmunity in MS [243]. Besides, phenotypic expression and levels 
of EBNA1 has been associated with MS-related polymorphisms in HLA-DR and 
HLA-DQ genes, proposing an overlap in regions linked to EBV infection and self-
reactive immune response [62].  
Furthermore, titers of EBNA1-specific IgG differ during different points of 
time in disease course. Fluctuating titers of anti-EBNA1 are found to reflect alterations 
in volumes of T2 MRI lesions [244]. Also, increased humoral response to EBNA1 
could be a predictive marker for expanded disability status scale (EDSS) score [232], 
and the start of definite MS clinical course, because CIS patients appear to have rising 
levels of anti-EBNA1 antibodies just few years before the onset of definite disease 
course [245-247]. Increased serum level of antibodies specific to ten peptides derived 
from different regions of EBNA2 has also been reported in CIS patients. This may 
suggest how early EBV needs to act to provoke humoral response to latent antigens 
and promote MS pathogenesis [248]. 
EBV reactivation in the blood is reflected by increased load of IgM and IgA 
antibodies specific for EBV early antigen (EBV EA) as well as evident presence of 






occurrence of new MS episode but not during recovery periods, suggesting that EBV 
reactivation may contribute to increased disease activity [249]. In fact, detecting 
humoral response to EBV EA in the blood, thus peripheral EBV reactivation, has been 
linked to increased MRI activity, manifested by the formation of additional gadolinium 
enhancing lesions on MRI scans [232]. Others, however, could not find such 
correlation [250].  
Increased blood levels of soluble BAFF, a B cell survival factor that is involved 
in regulating T cell immune response, and stable MS course are shown to be 
concurrent. Whereas, increased humoral response to EBV antigens (particularly 
EBNA1 and  EBV lytic BOLF1 antigen) and MAP peptides have been found to occur 
when blood levels of BAFF are low [251]. 
In a case-control study performed on Iranian IM patients, levels of vitamin D 
during acute EBV infection were found to be markedly decreased in comparison to 
control group [252]. Both IM and poor levels of vitamin D are associated with MS 
risk. Thus, the two factors may interact in a pathway that eventually leads to 
developing MS [252]. Consistent with these findings, another study conducted on 
RRMS cohort, has revealed that low serum levels of vitamin D correlates with 
increased humoral response to EBNA1 which seems more pronounced in persons 
carrying HLA DRB1*1501 [81].  
Atrophy in grey matter, measured on MRI scan, has been linked to the level of 
antibodies directed to EBV VCA in MS patients but not in patients with other 
neurological diseases and healthy controls [253]. Also, humoral response to both 
EBNA1 and EBV VCA has demonstrated a significant correlation with volume loss in 







In addition to serology-based evidence, other case-control methodologies 
depend on linking levels of peripheral or intrathecal cell-mediated response specific to 
EBV and the risk of MS onset, and disease progression [254-258]. It has been reported 
that the CSF of both MS and controls diagnosed with other inflammatory neurological 
diseases (OIND) has heavily enriched immune response to EBV expressed proteins. 
This intrathecal EBV-reactive immune enrichment has been reported to be greater in 
MS patients than in OIND controls [259], and is translated into marked increase in the 
expression of inflammatory IFN-γ and TNF-α [259]. The augmented response of EBV-
reactive T cells in MS CSF is accompanied by reduced response of EBV-reactive T 
cells in the blood. This suggests that preferential expansion of CSF EBV-reactive T 
cell population may be an intermediate route for T cells transmigrating to MS brain 
[259]. Additionally, this response seems specific to EBV, because no expansion has 
been seen in intrathecal CMV-specific T cell population in either MS or OIND 
patients. Prolonged administration of daclizumab high-yield process (DAC HYP), 
blockade monoclonal IgG1 for CD25 (IL-2R α subunit) expressed on T cells, has been 
found to restore the number of EBV-reactive T cells in the blood and CSF of RRMS 
patients back to uniform distribution [259]. Since intrathecal amplification of EBV-
reactive T cells has been found in MS and OIND patients, EBV may be a global 
characteristic for neuroinflammatory conditions. Analysis of MHC class I-binding 
pentamers has recently shown similar levels of CD8+T lymphocytes reactive to 
‘HPVGEADYFEY’ epitope (derived from EBNA1 antigen) in MS and OIND patients 
[260].   
Lately, it has been demonstrated that different neuronal cell lines are infectable 
by gammaherpesviruses EBV and KSHV using recombinant protein-tagged virus 






latent and lytic cycle of EBV infection as manifested with the expression of EBNA1 
and BZLF1, respectively. Therefore, these cell lines could serve as models for studying 
potential pathologic events resulting from the presence of EBV in the CNS [261]. 
Although access to brain tissues, particularly fresh tissues, is not as easy as 
collecting blood or CSF samples, a number of postmortem studies investigating EBV 
association with MS continues to accumulate. In 2007, Serafini and co-investigators 
looked at 34 blocks of autopsied cerebral tissues from 22 MS cases [262]. EBV has 
been found in 21 MS cases and none in 11 control brain tissues. EBV has been 
localized within CNS-infiltrating (CD20+) B cell and (CD138+) plasma cell 
population, particularly the subsets making up lymphoid aggregates resembling 
peripheral B cell follicles. EBV infected cells have been found to express a subset of 
viral latent (LMP1, EBNA2) and lytic (BFRF1) antigens in acute MS. It has been 
shown that EBV infected plasma cells are a target for perforin secreting CD8+ T cells. 
These observations led the authors to conclude that EBV reactivation and disturbed 
virus-host homeostasis may contribute to MS inflammation [263].  
Another study performed on a limited number of autopsied brain tissues 
reported MS tissue-specific expression of lytic BZLF1 in heavily infiltrated meninges, 
where immune cells cluster forming B cell-like follicle structures, and within 
perivascular infiltrates in active white matter lesions [264]. These lytically infected 
cells, however, have not been found in other types of white matter lesions (chronic 
active and inactive). Up to 10% of all BZLF1 positive cells have been found to 
coexpress markers of Ig-positive plasma cells [264]. These results were replicated by 
another study utilizing brain tissues from SPMS-diagnosed individuals [265]. The 
expression of EBV lytic antigens (BZLF1 and BFRF1) has been shown in inflamed 






postmortem cases, the physical presence of EBV has been demonstrated in active 
white matter lesions with pronounced IFNα immunoreactivity within infiltrating 
microglia and macrophages [266]. In contrast to these studies, other groups have not 
found any evidence of EBV infection in the brain in MS cases [267-269]. 
1.9 Hypothesis and Objectives of the Study 
While medical research’s purpose in MS has not changed -find the cause to 
find a cure-, where to look and how to look should be cautiously considered not to end 
up chasing a vague will-O’-the-wisp. The body of data implicating role of EBV in MS 
pathogenesis is growing. In light of the above mentioned observations and 
controversies, this project was aimed to address if EBV is a cofactor etiologically 
involved in the pathogenesis of MS and how. Defining the precise frame relating EBV 
to MS, if any, is highly important in establishing disease mechanism and risk 
estimation, therefore help prevent MS or better treat MS patients. 
In this study, we aimed to 1) determine if EBV is present in MS lesions using 
a large sample size from MS and non-MS cases, 2) determine EBV viral load in MS 
using quantitative PCR, 3) assess possible mode of entry of EBV to the brain, and 4) 






Chapter 2: Materials and Methods 
 
2.1 Postmortem Brain Slices and Subjects Details 
All experiments were carried out on autopsied human brain tissues procured 
from Rocky Mountain Multiple Sclerosis Centre (RMMSC) tissue bank, University of 
Colorado (Denver, CO, USA).  Tissues were handled per established protocols of the 
RMMSC brain tissue bank, and sliced into multiple coronal full hemispheric sections. 
We received at least 1 coronal section, representing a specific anatomical region of the 
human brain (figure 2.1), per postmortem case. All received slices were fixed and 
stored in 10% buffered formalin.  
A total of 135 brain slices representing 129 cases were stratified into 2 cohorts. 
MS cohort included cases with clinical history of MS, and non-MS control cohort 
included cases that never carried a definitive diagnosis of MS during their life time. 
Whenever available, autopsy reports provided information about subjects’ age, sex, 
cause of death, and gross pathology and histopathology of the brain. The clinical 
course was indeterminate in 7 cases, thus they were excluded from data analysis. In 







Figure 2.1: Coronal sections of human brain. The slices represent different 
anatomical areas of the brain. Image retrieved from 
http://www.mci.gr.jp/BrainBank/complete.jpg 
2.1.1 Non-MS control cases 
Control cohort was represented by 21 cases, 9 of which had a conspicuous brain 
pathology at autopsy. They included Alzheimer's disease, progressive supranuclear 
palsey-like tauopathy, meningioma and ischaemic brain injury. None of the 21 control 
cases had any evidence of MS demyelinative plaques at autopsy, or MS clinical signs 
during the life of the individual. Age of the controls at death ranged from 25 weeks of 
gestation to 76 years. This cohort contained 15 males representing 71% of the non-MS 
group. Demographics of non-MS control cases are summarized in table 2.1. 
Control cases Number of cases Age at death 
Males 15 51±27 (25 weeks of gestation-76) 55 
Females 5 51±11 (38-63) 52 
Total cases 21 51±24 (25 weeks of gestation-76) 55 
 
Table 2.1: Demographics of non-MS control cases. Age at death, unless otherwise 
stated, in years; expressed as mean± standard deviation, with data range in brackets 






2.1.2 MS cases 
There were 101 cases in the MS cohort, predominantly consisting of females. 
Mean age at death in the MS female group was 65±13 years old. One third of the cohort 
was represented by males, with mean age at death 60±13 years old. Overall, cases in 
this cohort suffered from MS for a duration of 7- 60 years before dying at ages ranging 
between 29 and 98 years old. Clinical data of MS cases is summarized in table 2.2. 
Detailed clinical data of both cohorts are in appendix I. 
MS  Number of cases  age at death Age at MS onset MS duration 
Males 33  60±13 (42-98) 59 30±12 (28-51) 35  18±9 (10-30) 17 
Females 68 65±13 (29-92) 66 32±13 (16-53) 29  27±16 (7-60) 21 
Total  101 63±13 (29-98) 64 34+-12 (16-53) 32  24+-15(7-60) 20 
 
Table 2.2: Clinical characteristics of MS cases. Age at disease onset, age at death and 
disease duration in years; expressed as means ± standard deviation, with data range 
in brackets followed by the value of the group median 
The severity of MS plaques was described in most of the cases as ranging from 
‘moderately severe to severe burden’. This was consistent with the gross appearance 
of some of the received coronal sections which showed few relatively depressed areas. 
These areas were some-what tan-discoloured, shape defined, and difficult-to-cut. 
Cerebral deep white matter, periventricular white matter, cerebellum, optic nerve and 
chiasm, and brainstem were the most frequently reported areas to be affected by MS 
demyelinative plaques. About 75% of the characterized cases were reported at autopsy 
to be ‘chronic inactive’ MS. This was based on tissue lesions evaluated by histologic 
(haematoxylin and eosin) and special stains (Luxol Fast Blue-Periodic Acid Schiff) 
and immunohistochemistry (mainly for MBP and macrophage CD 68). A minimum 
number of cases had myelin breakdown activity. Seven cases were reported to have 






Nine cases were explicitly placed under progressive MS category, the majority 
being secondary progressive multiple sclerosis (SPMS). According to autopsy reports, 
spinal MS was identified in 7 cases, mainly affecting cervical region. In as many as 
half of the examined cases, MS gross pathology included cerebral atrophy, thinning of 
the corpus callosum, and enlargement of the ventricles and hydrocephalus ex vacuo. 
Although meningeal fibrosis was identified in some cases, almost all cases were 
described devoid of meningeal inflammation. Perivascular lymphocytic cuffing was 
identified microscopically in 17 cases. Also, in few cases MS demyelinative plaques 
coexisted with 1-2 different neuropathologies; specifically Parkinsonism, Alzheimer’s 
disease, progressive multifocal leukoencephalopathy, immune reconstitution 
inflammatory syndrome, atherosclerosis and arteriolosclerosis.  
The brain tissues were preserved in formalin for a varying period of time, 
ranging from 2 to 23 years (mean± standard deviation (SD) was 13±7 years). However, 
the majority of the cases were preserved for a period that lasted for 5-16 years. The 
mean time interval from death to fixation was 16 hours (postmortem interval ranged 
from 4 to 41 hours). This study was approved by the local institutional ethics review 
board, Al Ain Medical District Human Research Ethics Committee (application 
number AAMD HREC 12/95). 
The experiments carried out in this thesis, followed the criteria of an 
observational case-control design. This design allowed us to easily compare inter- and 
intra- group variables in situ (differences within the site of ailment) and draw 
rationalized conclusions that open doors for new hypotheses about the involvement of 
infectious agents such as EBV in an autoimmune disorder such as MS. However, one 
must bear in mind that with this type of study design, certain biases can be introduced 






from retrospective records. The latter may interfere with outcome interpretation 
particularly when common confounding factors, namely age, gender and ethnicity are 
involved. Thus, a large number of samples was used to minimize the probability of 
type II error.  
2.2 Workflow of Processing Brain Coronal Slices 
Each brain slice was handled in a sterile disposable petri dish. The required 
areas were cut with a sterile scalpel. All tools including scalpel blade and forceps were 
thoroughly sterilized to avoid cross-contamination between samples. From each case, 
small pieces of tissues were cut in the following order: 
1- Single small piece from white matter area was cut and placed into a sterile 
disposable 15-ml centrifuge tube (product #430790, Corning). The tube was filled 
with 1xPBS buffer for washing out the fixative and preparing for genomic DNA 
extraction process. 
2- Three more small pieces were cut from 3 different white matter regions (referred 
to as white matter replicas), with the third one being cut from the grey matter-
white matter junction. White matter replicas were placed in tissue 
processing/embedding cassettes and processed to paraffin blocks.   
3- Maximum of 3 small pieces were cut from 3 different meningeal areas (referred 
to as meningeal replicas), placed into a 1xPBS-filled 15 ml centrifuge tube and 
processed for genomic DNA extraction. 
4- Maximum of 3 small pieces were cut from 3 different meningeal areas, placed in 
tissue processing cassettes and processed to paraffin blocks. An outline of the 














2.3 Extraction of DNA from Long-Term Formalin Preserved Brain Tissues 
As mentioned above, the brain slices used in this study have been stored in 
formalin for long time. It is an established fact that tissue fixation in formalin 
introduces dramatic changes at the molecular level. Formaldehyde, a lab biohazard and 
one of the most commonly used aldehyde fixatives, is a gas of small molecular weight. 
This gas saturates into the aqueous state in the form of 37% formaldehyde solution. In 
lab settings, 4% formaldehyde is used in a buffered solution. A buffered solution 
serves as a pH stabilizer and is essential to avoid oxidization of formaldehyde and 
buildup of formic acid, which decreases the pH of the fixative, and produces unwanted 
effects in the fixed tissue [270].  
Due to its efficient speed in both tissue penetration and fixation [270], formalin 
is a good fixative for retaining tissue morphology and histological staining. It, 
however, exerts profound limitations on the quality and quantity of nucleic acids that 
can be extracted from such tissues. Formalin has been found to cause its fixative effect 
through introducing cross-linking bonds between lysine residue and side chain of 
various amino acids such as lysine, arginine, histidine and glutamine. Not only does 
this cross-linking affect proteins, but can also directly or indirectly disturb nucleotides 
organization and extend to the nearby histones [271].  
Consequently, recovery of nucleic acids of good quality and quantity can 
become challenging, if not impossible, as a result of time-dependent nucleic acid 
degradation and sequence alteration [272]. This severe limitation of the usage of 
formalin preserved archival tissues has forced scientists to come up with numerous 
different ‘nucleic acid friendly’ fixatives that can substitute formalin [273], use fresh 






recovery of genomic DNA. Therefore, in this work we optimized multiple factors in 
the DNA extraction process in order to obtain the best possible quality of genomic 
DNA. Using traditional phenol-chloroform biphasic extraction, the following steps 
were initially followed before progressive amendments were introduced to tackle the 
PCR inhibitory effects of extracted DNA: 
1- Each piece of brain tissue (~250 mg) was cut and placed in a 15 ml tube filled 
with 1xPBS (pH 7.4). 
2- Formalin, the fixative solution, was washed out by washing the tissue in 2 changes 
of 1xPBS buffer (1xPBS: 137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4, 1.4mM 
KH2PO4). 
3- In the final 1xPBS wash, the tissue was homogenized using the homogenizer 
(ULTRA-TURRAX, T-25), for ~2 minutes or until the tissue was uniformly 
homogenized.  Meninges were macerated with a pestle on a sterile petri dish rather 
than with the homogenizer. Using the latter would increase the possibility of 
cross-contamination between samples.  
4- The homogenate was spun down at room temperature at 4000 rpm for 5 minutes, 
(Allegra X-15R centrifuge, Beckman Coulter, USA). 
5- The washing buffer (1xPBS) was discarded, and 2 ml of sodium dodecyl sulfate 
(SDS)/ proteinase K-based digestion buffer (TENS buffer) was added. This buffer 
consisted of 10mM Tris, pH 7.5, 400mM NaCl, 100mM EDTA, 1% SDS and 0.5 
mg/ml proteinase K (Cat No. P6556, Sigma).  
6- Tissue homogenate was mixed well with the digestion buffer by continuously 







7- At the end of the incubation period, proteinase K enzymatic reaction was stopped 
by spinning down the lysate at room temperature for 15 minutes at 4000 rpm. 
8- Supernatant was pipetted off and transferred to a new sterile centrifuge tube. 
9- For genomic DNA extraction, phenol–chloroform–isoamyl alcohol (25:24:1, 
Sigma, USA) was then added (under a fume hood due to its toxicity) to the lysate 
in 1:1 volume ratio and mixed thoroughly (by continuously inverting the tube).  
10- The mixture was then spun down at 4000 rpm for 15 minutes at room temperature, 
to separate the 2 phases (lower organic and upper aqueous phases) with an in-
between fuzzy rim that is kept minimal by chloroform. 
11- The supernatant was pipetted off with caution to avoid contamination with the 
interphase which could reduce the purity of the recovered DNA. This aqueous 
supernatant was transferred to a new sterile centrifuge tube.  
12- Phenol-chloroform extraction step was repeated once more to ensure extraction of 
pure and protein-free DNA. 
13- DNA was precipitated by adding 1/10th the volume 3M sodium acetate and cold 
absolute ethanol (AppliChem, 131086) in 1:1 volume ratio. 
14- The mixture was incubated at -20˚C overnight or at -80˚C for 3-4 hours. 
15- The mixture was spun down using a bench centrifuge at maximum rpm for 30 
minutes. Salted ethanol was discarded. 
16- Cold 70% ethanol was added to wash precipitated DNA. The mixture was spun 
down at maximum rpm for 5 minutes and supernatant was discarded. 
17- The pellet was air-dried, subsequently ~50 µl nuclease-free water or TE buffer 






18- DNA amount and purity were estimated using NanoDrop-1000 instrument 
(Nanodrop Technologies, USA) by measuring the absorbance at 260 and 280 nm 
(A260/A280 ratio).  
These steps were performed taking all possible precautions to avoid DNA 
contamination. Also, genomic DNA from an EBV-positive control, B95-8 cell line, 
was extracted following these steps. The outcome of this protocol was then compared 
with that of: 
1- Commercial DNA extraction kits. (QIAGEN (QIAamp DNA Mini Kit) and 
Promega (Wizard® Genomic DNA Purification Kit)) 
2- DNA extracted from paraffinized and deparaffinized tissues. The rationale 
behind this was that tissue processing pre-paraffin embedding and post-dewaxing 
could potentially eliminate tissue fixative and other PCR inhibitory components:  
a- Small pieces of tissue were cut, placed in a histology cassette, then processed 
(see tissue processing section 2.7) and embedded in paraffin wax.  
b- The paraffin block was sectioned using the microtome at thickness of 10 µm. 
Three 10 µm sections were collected in 1.5 µl-Eppendorf tubes. 
c- To deparaffinize the tissue, 500 µl xylene (Sigma, 16446) was added (under 
fume hood) and incubated at room temperature for 15 minutes. 
d- Tubes were spun down at 13000 rpm for 10 minutes. The supernatant (wax 
dissolved in xylene) was discarded.  
e- To completely eliminate xylene, 500 µl absolute ethanol was added and 
incubated at room temperature for 15 minutes, and step ‘d’ was repeated. 
f- Finally, tissues were treated with SDS/PK-based digestion buffer and 
incubated at 55˚C for 24 hours. Subsequently, phenol-chloroform extraction 






3- Changing/ optimizing content of digestion buffer. 
In a separate experiment, the above defined TENS digestion buffer was substituted 
with a buffer containing 500mM TRIS, pH 9.0, 20mM EDTA, 10mM NaCl, 0.1% 
SDS and 0.5 mg/ml proteinase K (referred to as optimized digestion buffer), 
keeping all other steps constant. 
4- Changing/ optimizing protein digestion (I): optimizing proteinase K 
concentration. 
In a separate setup, 4 weight-equal tissues were incubated with the optimized 
digestion buffer for only 24 hours. Each tissue (represented with 5 replicas) was 
treated with 5 different final concentrations of proteinase K; 2.5, 1.25, 0.62, 0.31 
and 0.15 mg/ml simultaneously. DNA quality, quantity and amplifiabilty were 
checked to determine the best proteinase K concentration required for DNA 
extraction. 
5- Changing/ optimizing protein digestion (II): optimizing the length of 
incubation with proteinase K. 
In a separate experiment, 26 tissues were incubated with the optimized digestion 
buffer. After 39 hours of incubation the reaction was stopped for 8 samples, and 
the rest of samples continued incubation. After 68 hours from the start of 
incubation the reaction was stopped for another 10 samples. The remaining 8 
samples were incubated for a total 116 hours in the digestion buffer. DNA quality, 
quantity and amplifiabilty were checked to determine the best length of 
incubation. 
6- Other minor changes: extensive washes, DNA salted precipitation, and 






a- As a way of eliminating formalin from the tissues, tissue homogenates were 
washed with 6-10 changes of 1xPBS. In each wash, tubes were continuously 
inverted on the tube rocker to ensure thorough wash. 
b- In DNA precipitation step, adding 1/10th the volume 3M sodium acetate was 
substituted with adding 1/5
th  the volume 0.1M sodium chloride. 
c- Three different concentrations of MgCl2 were tested; 2mM, 3mM and 4mM. 
Quality control parameters were then checked including:  
1- Quantity (amount of DNA extracted as determined by NanoDrop-1000 
spectrophotometer). 
2- Purity (good 260/280 ratio). 
3- Quality (extent of DNA fragmentation) determined by sizes of DNA 
fragments by gel electrophoresis of 5 μl of the extracted DNA using 1.5% 
agarose gel stained with ethidium bromide in 0.5x TBE (0.9M Trisma Base, 
0.9M Boric Acid, and 0.5M EDTA, pH 8.0) buffer.  
4- Amplifiability (overcoming inherent PCR inhibition and obtaining PCR 
amplicons). Once all parameters were optimized for the recovery of 
genomic DNA of good quality and quantity for the downstream molecular 
work, genomic DNA was extracted from all 122 cases. DNA was extracted 
from a single white matter area from each case, and from 3 different 
meningeal areas. Due to the increased fragility of the meninges, particularly 
with the harsh conditions found in formalin fixation for years, it was not 
always possible to obtain 3 replicas of meninges. Thus, some cases were 






2.4 Standard PCR: PCR Amplification of EBV BamHI W Fragment 
Concentrated DNA was diluted to roughly 50 ng/µl per aliquot. For PCR 
internal control, 3 house-keeping genes were used to check for the suitability of the 
extracted DNA for PCR amplification: (a) β-globin (amplicon size 104 bp) (GenBank 
ref.: NM_000518.4) [275], (b) GAPDH (amplicon size 351 bp) [276], and (c) GAPDH 
(amplicon size 560 bp) (GenBank ref.: M33197) [277]. Primer sequence is listed in 
table 2.3. 
PCR reaction was carried out in a 30 μl final volume. The reaction was 
composed of 1× PCR buffer, 10pmol of forward and reverse β-globin primers, 1× Q 
solution (QIAgen), 0.05mM of deoxynucleotides, 1 unit of Taq DNA polymerase 
(QIAgen), and 100 ng of genomic DNA. Genomic DNA extracted from B95.8 was 
used as positive control, while at least 2 negative controls consisting of nuclease-free 
water (or no DNA template) were used to monitor PCR contamination. Applied 
Biosystems thermal cycler PCR System 2700 was used with the following thermal 
cycling conditions: initial denaturation step at 94°C for 5 minutes, 40 cycles of brief 
94°C denaturation (1 minute), annealing temperature for β-globin at 55°C (45 seconds) 
and elongation at 72°C (30 seconds). PCR was concluded with a final extension of the 
full PCR product at 72°C (5 minutes). Amplicons were electrophoresed in 2% agarose 
gel stained with ethidium bromide.  
Once PCR internal control was confirmed, amplification of relatively small 
EBV-specific primers flanking portion of EBV Bam H1W internal repeat sequence 
was performed. PCR for EBV BamHI W 152 bp-fragment (table 2.3) [163] was carried 
out following the same PCR reaction ingredients as with the house-keeping genes. The 






2.5 PCR Amplification of Three Common Human Herpesviruses 
Sixteen white matter DNA samples, positive for EBV, were randomly selected 
and screened for the presence of other ubiquitous herpesviruses. PCR primers for 3 
viral genomes (reside latently in a large percentage of human population) were selected 
to flank short sequences that would allow DNA of average integrity to be successfully 
amplified. The first pair of primers were used to amplify a conserved 92 bp sequence 
within DNA polymerase gene-coding region from herpes simplex virus-I (HSV-1) 
[278]. The second pair of 20-mer primers flanked 139 bp sequence in cytomegalovirus 
(CMV) genome [279], and the last pair was chosen to amplify a target sequence of 137 
bp within human herpes virus type 6 (HHV-6) genome (table 2.3) [279]. PCR thermal 
conditions were kept constant for all primers; with 40 cycles of amplification. The 
annealing temperatures for HSV, CMV and HHV-6 primers were 63˚C, 62˚C, and 
53˚C respectively. 
Genomic fragment Primers sequence Product size (bp) 
β-globin F: 5' GAG GTT CTT TGA GTC CTT TGG 3' 
R: 5' CAT CAC TAA AGG CAC CGA GCA 3' 
104 
GAPDH  F: 5' GCC TCC TGC ACC ACC AAC TG 3' 
R: 5' CGA CGC CTG CTT CAC CAC CTT CT 3' 
351 
GAPDH  F: 5' CAT GTT TGT GAT GGG TGT GAA CCA 3' 
R: 5' GTT GCT GTA GCC GTA TTC ATT GTC 3' 
560 
EBV  F: 5' CAC TTT AGA GCT CTG GAG GA 3' 
R: 5' TAA AGA TAG CAG CAG CGC AG 3' 
152 
HSV-1  F: 5' CAT CAC CGA CCC GGA GAG GGA C 3' 
R: 5' GGG CCA GGC GCT TGT TGG TGT A 3' 
92 
CMV F: 5' CCG CAA CCT GGT GCC CAT GG 3' 
R: 5' CGT TTG GGT TGC GCA GCG GG 3' 
139 
HHV-6 F: 5' TTA AAC AGC CGT TGT CAG GG 3' 
R: 5' GTA TCC CGA CGG CAG AGG TT 3' 
137 
 
Table 2.3 Sequence of PCR primers. Primers were used in amplifying genomic DNA 
extracted from brain tissues 
2.6 Quantitative Real-Tme PCR 
To determine EBV viral load in the brain, quantitative real-time PCR (qPCR) 






and meninges. This method for quantifying EBV DNA has been previously described 
[163] and was applied to all EBV positive white matter DNA, and to EBV positive 
meningeal DNA that were positive for EBV in at least 2 replicas by standard PCR. 
EBV positive replicas from the same case were pooled into one 50 ng/µl aliquot.  
The very first step in qPCR was establishing a standard calibration curve of 
EBV- positive control DNA, from which viral copy numbers in test samples could be 
extrapolated. To establish a standard curve we used Namalwa cell line (CRL-1432, 
American Type Culture Collection), an EBV positive Burkitt's lymphoma cell line in 
which 2 integrated copies of EBV genome reside within each cell. Ten-fold serial 
dilutions of Namalwa DNA (100, 10, 1, 0.1, and 0.01 ng/µl) were prepared, run in 
duplicates and quantified by qPCR. Then, generated mean value of cycle threshold 
(Ct) of duplicate wells for each dilution was taken, and plotted against the logarithm 
of DNA amounts of the serial dilution of Namalwa genomic DNA. Establishing a good 
standard curve was ensured through observing good correlation coefficient. White 
matter and pooled meningeal DNA were also run in duplicates and Ct mean values 
were generated by qPCR. BamH1W assay was most sensitive, presumably because it 
targets a reiterated sequence that is present at approximately 10 copies per EBV 
genome [280]. 
Quantitative PCR reaction was set up in dark laminar flow hood using 
MicroAmp® Optical 96-well Plates (Applied Biosystems). The work area was cleaned 
with 70% ethanol and UV-irradiated for 15 minutes prior to setting up the reaction. 
Also to reduce potential contamination, a separate set of sterile pipettes designated for 
PCR work were used. To monitor contamination, nuclease-free water was included in 
at least 4 wells as negative control. Also, it was essential to minimise pipetting error 






well and pipetted cautiously. Each reaction took place in a final volume of 20μl, 
containing 1x TaqMan Universal PCR Master Mix, 1x primer-probe mixture, 50ng of 
DNA template, and 8 μl DNase-free water.  
Once individual reactions were set up, the plate was covered with an optical 
strip (adhesive cover) and spun down at 3000 rpm for 2 minutes before placing it into 
Applied Biosystems 7500 real-time PCR machine (Applied Biosystems, Germany). 
BamHI W primer-probe combinations (forward: 5`GCA GCC GCC CAG TCT CT3`, 
reverse: 5`ACA GAC AGT GCA CAG GAG CCT-3`, and probe: 5`(6FAM) AAA 
AGC TGG CGC CCT TGC CTG (TAMRA)-3`) were custom-designed according to 
published sequences [280] and acquired from Applied Biosystems. The probe was 
labeled with FAM, a fluorescent tag emitting a spectrum upon excitation by prism at 
488 nm. EBV BamHI W amplification conditions were as follows: 5 minutes at 95°C, 
and then 40 cycles of denaturation at 95° C for 15 seconds, annealing at 60°C for 1 
minute and extension at 72°C.  
2.7 Processing of Formalin Preserved Tissues 
Formalin fixed brain tissues were processed in a fume hood because of the 
well-documented toxicity of formalin. Small pieces of tissues were cut out from each 
coronal slice on a formalin-filled sterile petri dish using a sterile disposable blade to 
avoid carryover contaminants between cases. Tissues with a mean thickness of 3 mm 
and mean dimensions 1.5x1 cm were cut from brain parenchyma (white matter and 
white matter-grey matter junction) and meninges as mentioned earlier (figure 2.2). 
Tissues were placed on a filter paper and transferred into pre-labelled histology 






orientation of the tissue was maintained in such a manner that the surface of the tissue 
that was intended to be sectioned first faced the bottom of the cassette. 
1- First, formalin was discarded, and cassettes were incubated in series of graded 
ethanol, 30%, 50%, 70%, and 90% (each for 45 minutes). Cassettes were then 
incubated in 2 changes of absolute ethanol (each for 1 hour) to eliminate all water 
from the tissues. 
2- Tissues were cleared with xylene, by incubating cassettes in ethanol-xylene 
mixture (1:1 volume ratio) for 45 minutes, and after that in 2 changes of absolute 
xylene for 30 minutes each. 
3- For paraffin impregnation, cassettes were incubated in 3 changes of molten 
paraffin wax (Histoplast PE, Thermo Scientific, Ref. No. 8330) in 60˚C oven, each 
for 30 minutes. 
4- Tissues were then embedded into wax blocks using moulds of appropriate size. 
Finally, blocks were trimmed to remove excess wax from all sides so it could fit 
perfectly in microtome block holder. 
5- Microtomy: cold paraffin blocks were levelled using rotary microtome at 10-15 
µm thickness to get rid of excess wax on block surface. Tissues were then 
sectioned at 5µm thickness. The produced ‘ribbons’ were floated on a 40˚C water 
bath, and collected using silanized (coated) slides. Coating slides (appendix III) 
with 3-aminpropyltriethoxysilane (Sigma, A3648) prior to using them is essential 
for tissues to stay adherent to slides and eliminate detachment. 
6- Slides were dried on warm plate, ready to be stained. A summary of tissue 








Figure 2.3: Tissue processing workflow. Processing started with cutting out the target 
area from brain coronal slice, to undergo series of dehydration, clearing and wax 
impregnation before reaching embedding facility; where it was blocked out in 
moulds, and subsequently trimmed to go through microtomy. Finally, sections were 
collected in a warm water bath using coated slides and dried overnight 
2.8 Localization of EBV Infected Cells Using EBER In Situ Hybridization 
In situ hybridization (ISH) for EBV encoded RNAs (EBERs) was performed 
as previously described in detail [156]. Briefly, two oligonucleotide probes were 
custom-designed for the detection of EBERs. Anti-EBER1 is an antisense probe 
consisting of 30-nucleotides complementary to a sequence stretching from position 91 
to 120 on EBER1. Anti-EBER2 is the second antisense probe consisting of a 30-mer 
sequence complementary to nucleotides stretching from 82 to 111 nucleotides on 







Figure 2.4: EBERs structural prediction. Anti-EBER1 and Anti-EBER2 
oligonucleotide probes bind to the blue highlighted sequence on EBER1 and the pink 
highlighted sequence on EBER2, respectively [281] 
Each one of the 2 antisense probes was end-labelled individually with 
Digoxigenin molecule (DIG) using commercially available end-labelling kit (Cat # 
03353583910, Roche) (figure 2.5) as follows:  
a- 4 µl 5x tailing buffer: 1M potassium cocodylate, 125mM Tris-HCl, 1.25 mg/ml 
bovine serum albumin, pH 6.6, 
b- 4 µl CoCl2 solution (25mM), 
c- 1 µl Dig-dUTP (1mM Dig-11-dUTP in ddH2O), 
d- 1 µl dATP (10mM in ddH2O), 
e- 1 µl terminal transferase (400 U/µl), 
f- 1 µl probe (1 µg/µl), and 







Figure 2.5: End labelling probes with DIG. The reaction is catalysed by terminal 
transferase. Image retrieved from https://lifescience.roche.com/shop/products/dig-
labeling-methods 
After mixing the tubes well, they were incubated in 37°C heat block for 30 
minutes. The reaction was stopped by adding 2 µl of 0.2M EDTA (pH 8.0). At this 
stage no purification was needed, because the nucleotides that were not incorporated 
would be washed off during the stringency wash, a critical step during EBER-ISH. 
Finally, the volume of the labelled probe was made up to 100 µl by adding 78 µl of 
sterile TE buffer (50mM Tris-HCl, 1mM EDTA, pH 7.6). Thus, the concentration of 
the labelled probe was 10 µg/ml. Then, the 2 labelled probes were mixed together. To 
create negative control probes, sense probes of non-complementary sequence to the 
same segments of EBER1 and EBER2 were labelled with DIG in a similar reaction to 
that described above. The two sense probes were mixed together (final concentration: 
10 µg/ml). Once the probes were labelled, EBER-ISH was carried out as following: 
1- Slides were warmed in a 60°C oven for an hour to melt the wax, and sections were 
deparaffinised in 2 washes of xylene, each for 10 minutes. Sections were then 
dehydrated in graded ethanol (70%, 90% and 100%), each for 5 minutes. 
2- The activity of endogenous tissue peroxidase was quenched using 0.5% H2O2 
(30% w/v, Panreac, 121076) in methanol (Panreac, 131091) for 20 minutes. 
Sections were then dehydrated in absolute ethanol for 2 minutes, and air dried. 
3- In a 37°C humid incubator, sections were incubated with a 150-200 µl volume of 






concentration 100 µg/ml) for 10 minutes. The reaction was stopped by washing 
slides in water, and slides were dehydrated in absolute ethanol. 
4- Then, slides were incubated with 25 µl volume of hybridization solution, 
consisting of 10 µg/ml labelled probes diluted 1:50 (final working concentration 
0.2 µg/ml) in hybridisation buffer (50% formamide, 5% dextran sulphate, 2x SSC) 
(appendix II). Coverslips of a dimension 32x22 cm were used to cover the tissue. 
The coverslips helped spread the hybridization solution over the entire tissue, and 
eliminate evaporation. Then, slides were placed in a hybridization chamber 
humidified using wet filter paper (in 2xSSC). 
5- Labelled probes and target EBERs were denatured in a domestic microwave for 7 
minutes at the lowest power. Subsequently, overnight hybridization was carried 
out in a 42°C oven. 
6- On the following day, coverslips were removed and sections were washed in 2 
changes of 2xSSC, each for 10 minutes.  
7- After that, stringency wash was done to get rid of unbound probe and eliminate 
non-specificity. Slides were incubated in 2 changes of pre-warmed 0.1xSSC at 
50°C, each for 10 minutes. 
8- Slides then were washed in 2 changes of 2xSSC, followed by a wash in 1xPBS, 
each for 5 minutes. 
9- Sections were incubated for 30 minutes at room temperature in a humidified tray 
with the primary antibody. For this, a solution of 150-200 µl was added per 
section. Monoclonal mouse anti-DIG antibody (clone D1-22, Sigma Cat# D8156) 
was diluted at 1:2500 in 1x PBS containing horse serum diluted at 1:100 provided 






Cat# 32052). Unbound primary antibody was then washed off in 3 changes of 
1xPBS, each for 10 minutes. 
10- Sections were incubated for 30 minutes with 150-200 µl of biotinylated anti-
mouse secondary antibody (Thermo Scientific, Cat# 32052) diluted 1:200 in 
1xPBS containing 1:100 diluted horse serum. Sections were washed in 3 changes 
of 1xPBS, each for 10 minutes. 
11- The ABC solution (Thermo Scientific, Cat# 32052) was prepared 30 minutes prior 
to its use to stabilize, by diluting each of reagent A (avidin) and reagent B 
(biotinylated peroxidase) 1:50 in 1xPBS. Tissues were incubated with 150-200 µl 
of ABC solution for 30 minutes in a humidified tray. Sections were washes in 
1xPBS. 
12- The color of the reaction was developed by adding 1ml of 25 mg/ml 3, 3′-
diaminobenzidine (DAB) (Sigma Cat# D5637) to 100ml 1xPBS containing 0.02% 
hydrogen peroxide (final concentration of DAB 250 µg/ml). Slides were incubated 
in DAB solution for 20 minutes. A control slide would be checked under the 
microscope after 20 minutes to ensure brown color development. If the color was 
thought to be underdeveloped, slides would continue incubation with DAB for 
maximum of 10 minutes more. 
13- Slides were rinsed in tap water, and then briefly counterstained with freshly 
filtered Harris hematoxylin (Shandon Instant Hematoxylin, Thermo Scientific, 
Cat. #6765015) for 2 minutes. Subsequently, slides were rinsed in water, 
decolorized for ~1 minute in acid alcohol (1% HCl in 70% ethanol), and blued in 






14- Slides were then dehydrated in absolute ethanol followed by thorough air dry, 
cleared in xylene, coverslipped using xylene based DPX mounting medium 
(Sigma, Cat # 06522), and observed under a light microscope (Olympus BX51). 
Assessment criteria: based on number of positive cells per section, cases were 
divided into ‘+’ for 1- 49 EBV positive cells, ‘++’ for 50-200 EBV positive cells, and 
‘+++’ for >200 EBV positive cells; i.e. heavily infected. For histopathology remarks 
such as inflammatory cell infiltration, hematoxylin and eosin (H&E) staining was also 
performed.  
2.8.1 Quality control for EBER-ISH 
Multiple controls were included for EBER-ISH to ensure correct staining 
procedure. First, both MS and non-MS cases were processed and stained under 
identical conditions. Second, a pretested positive control tissue was included in each 
batch. Positive control paraffinized tissue was either tonsil tissue from a patient 
diagnosed with EBV positive infectious mononucleosis or B95-8 cell line (an EBV 
positive marmoset cell line). Third, to verify specificity, negative control probes were 
included. For each tissue, one section was hybridized with labeled EBER antisense 
probes, and one section with EBER sense probes in parallel.  
Cases which were found to be EBER-ISH positive, were further confirmed by 
treating the tissues with RNase A prior to incubation with antisense probe. The signal 
should be removed after RNase treatment if the binding was specific to RNA in the 
tissue and not to another cellular target. For RNase treatment: 
1- Tissues were processed according to the above described EBER-ISH protocol. 
Once tissues were digested with proteinase K and subsequently dehydrated, they 






(Sigma, R5125) for 30 minutes. About 200 µl of 10 mg/ml RNase A diluted at 
1:50 in 2xSSC (final concentration 0.2 µg/ml) was added and spread evenly on 
each section. 
2- Tissue RNA digestion was stopped by washing slides in water. Slides were then 
dehydrated in absolute ethanol. 
3- Slides were incubated with EBER antisense probe and the EBER-ISH procedure 
performed as described above. 
2.9 Hematoxylin and Eosin Stain for Paraffinized Brain Sections 
1- Tissue sections were deparaffinized in xylene as described above, then hydrated 
in serial ethanol dilution (100%, 95%, 90% , 70% and 50%), each for 3 minutes, 
before bringing slides into water for 5 minutes, preparing them for the aqueous 
stain. 
2- Brain tissues were stained with freshly filtered Harris hematoxylin for 3 different 
periods of time; 5, 10 and 15 minutes. Brain tissues required long time to uptake 
the right crispness of hematoxylin stain, so sections were incubated in 
hematoxylin for 15 minutes. 
3- Slides were rinsed in water to remove excess hematoxylin and differentiated in 
1% HCl in 70% ethanol for one minute. Slides were then blued in running tap 
water for 10 minutes. 
4- Slides were rinsed in 95% ethanol for one minute and stained with Eosin Y (eosin 
in alcoholic solution, RAL diagnostics, UN1987) for 30 seconds. For 






5- Slides were washed and dehydrated in 3 changes of absolute ethanol, and cleared 
through 3 changes of xylene, 5 minutes each. Finally, slides were mounted and 
examined under the microscope. 
2.10 Determining EBV Gene Expression Using Immunohistochemistry 
Once EBV infection in the brain was revealed using EBER-ISH, we aimed at 
determining EBV viral gene expression in cases with heavy infection (>200 EBV 
positive cells). Immunohistochemistry (IHC) for EBV latent protein EBNA1 and EBV 
lytic protein BZLF1 was performed as follows: 
1- Tissue sections were briefly heated in 60˚C dry oven for 20 minutes, dewaxed in 
xylene and rehydration in graded ethanol. 
2- Because peroxidase-catalyzed IHC was performed, slides were incubated in 0.5% 
H2O2 in methanol for 20 minutes, to eliminate non-specific background staining. 
3- Slides were washed in water and incubated for optimized heat-induced antigen 
retrieval (explained in section 2.10.1). 
4- Slides where washed in water and incubated with 150-200 µl 5% bovine serum 
albumin (BSA) in 1xPBS in humidified chamber for 2 hours, to diminish 
background/ non-specific staining. Slides were incubated in the washing buffer, 
1xPBS- 0.1% Triton X-100 (Sigma, T-8787) for 5 minutes. 
5- Primary antibodies were titrated (table 2.4) to determine best working dilution. 
Mouse anti-EBNA1 (clone D810H, Thermo) and anti-BZLF1 (clone BZ1, Santa 
Cruz) were diluted 1:100 and 1:10, respectively in the washing buffer. Each tissue 
section was incubated with 150-200 µl of diluted primary antibody in humidified 
chamber at 4˚C overnight. Slides were washed the following day in 3 changes of 






6- Tissue sections were then incubated with 150-200 µl of the secondary anti-mouse 
antibody, diluted at 1:200 in the washing buffer in humidified chamber at room 
temperature for 1 hour. Slides were washed in 3 changes of the washing buffer. 
7- The ABC, DAB and counterstaining steps were carried out as described earlier in 
section 2.8, from step 11 onwards. 
8- Quality control for immunostaining with anti-EBNA1 and anti-BZLF was 
checked by including negative control slides which were incubated with non-
immune sera as a substitute of primary antibodies. B95-8, a replication-permissive 
cell line, was also included as a positive control tissue. 
2.10.1 Optimizing antigen retrieval 
Formalin fixation is well known to cause cross-linking of proteins in a tissue, 
let alone tissues aging in formalin, where by-products of prolonged fixation bind, mask 
or intervene with the structure of certain antigen epitopes [282]. This progressively 
decreases either the accessibility of the primary antibody to the target antigen, or the 
recognition of the primary antibody of the target antigen. In other words, antigen 
masking hinders antibody-antigen interaction and the ability to detect a particular 
antigen epitope in a tissue [282]. This has led to the birth of the concept of antigen 
retrieval (or antigen unmasking) for IHC when using formalin fixed tissues [283]. 
Some of the crosslinking effect can be reversed through certain chemical reactions 
such as heating and enzymatic reactions [284]. Heating [285] and applying the right 
pH [286, 287] is commonly used for retrieving formalin fixed antigens. Prior to 
applying primary antibody we tried multiple approaches to optimize 







1- No antigen retrieval 
2- Antigen retrieval using either discontinuous or continuous heating. Slides were 
immersed in a pre-boiled 10mM sodium citrate- 0.1% Triton X-100 pH 6.0 and 
heated in a domestic microwave for: 
a- three cycles of 3 minutes each 
b- two cycles of 6 minutes each 
c- one cycle of 10 minutes 
3- Comparing 2 sources of heat, microwave and hot plate. Slides were immersed in 
a pre-boiled 10mM sodium citrate- 0.1% Triton X-100 and heated for 10 minutes 
either in a domestic microwave at the highest power or on a hot plate at 150-
200˚C.  
4- Comparing 2 antigen retrieval solutions, 10mM sodium citrate- 0.1% Triton X-
100 pH 6.0 and 25mM Tris-HCl- 0.1% Triton X-100 pH 9.0. Slides were kept in 
the antigen retrieval solution on bench top till the temperature of the solution 
dropped to room temperature, then washed in water. 
2.11 Identifying the Phenotype of EBV Infected Cells Using Double Staining 
To determine the identity of EBV infected cells in the brain, cases with heavy 
infection were immunostained for some of the highly suspected cells based on cellular 
morphology observed in H&E staining. Following the above described IHC steps, 
tissues were incubated with anti-CD3 (a marker for T cells), anti-CD19 and anti-CD20 
(markers for B cells). All primary antibodies were titrated to determine optimal 
dilution (table 2.4). Anti-CD3 (clone PC3/188A, Santa Cruz), anti-CD19 (clone LE-
CD 19, Thermo), and anti-CD20 (clone L26, Thermo) were diluted 1:100, 1:100 and 






from a human tonsil as positive tissue control. For negative controls sections were 
incubated with 1:200 diluted normal horse serum in 1xPBS instead of the primary 
antibody. 
To further investigate the phenotype of cells infected with EBV in the brain, 
immunofluorescence staining (IF) was performed as follows: 
1- Slides were deparaffinised in xylene, hydrated in graded ethanol, and blocked for 
endogenous peroxidase activity. Heat-induced antigen retrieval was then 
performed. 
2- Slides were incubated with 5% blocking BSA for 2 hours and washed 
subsequently in the washing buffer (1xPBS-0.1% Triton X-100). 
3- Tissue sections were incubated with either rabbit anti-GFAP (glial fibrillary acidic 
protein, a marker for astrocytes, Dako) diluted 1:4000, or goat anti-Iba1 (ionized 
calcium-binding adapter molecule I, microglial marker, Abcam) diluted 1:500 in 
washing buffer. Incubation with primary antibodies was done at 4˚C overnight. 
Slides were washed the following day in 3 changes of the washing buffer. 
4- Tissue sections were incubated with fluorochrome-conjugated secondary 
antibodies for 1 hour at room temperature in the dark. Anti-rabbit- CY5 (Cy™5 
AffiniPure Donkey Anti-Rabbit IgG (H+L), Jackson ImmunoResearch, Code: 
711-175-152) and anti-goat-rhodamine (Rhodamine Red™-X AffiniPure Donkey 
Anti-Goat IgG (H+L), Jackson ImmunoResearch, Code: 705-295-147), were each 
diluted 1:100 in the washing buffer. Sections were washed in the washing buffer. 
5- Slides were rinsed in 1xPBS, mounted (Immu-Mount, Shandon, 238402), and 
visualized in a fluorescent microscope (Olympus BX51) using appropriate filters. 






We also used two-step IHC and one-step EBER-ISH to co-localize both 
EBERs and cellular markers in heavily infected cases.  
1- IHC staining for CD20 was carried out as described above. Once DAB/hydrogen 
peroxide was applied, tissues were washed, dehydrated in absolute ethanol and 
allowed to air dry. 
2- Tissue sections were briefly digested with proteinase K (as explained in section 
2.8, step 3). 
3- Tissue sections were hybridized overnight with labelled EBER probes, and 
stringency wash was carried out the following day as detailed above (section 2.8). 
4- Tissue sections were incubated with anti-DIG-alkaline phosphatase conjugated 
antibody at 1:1000 dilution for 1 hour at room temperature. Slides were washed 
in 1x PBS. 
5- Sections were incubated with ready-to-use Alkaline Phosphatase chromogen 
solution; BCIP-NBT (BCIP: 5-bromo-4-chloro-3-indolyl phosphate NBT: p-
nitroblue tetrazolium chloride) (ab7468). To select the optimal incubation period 
that resulted in the right stain and minimal background, tissues were incubated 
with BCIP-NBT for a varying amount of time (40 minutes, 60 minutes, 80 
minutes, and 4 hours). Optimal blue stain was developed at 80 minutes incubation. 
6- Slides were washed in distilled water, rinsed in 95% ethanol, and briefly stained 
with Eosin Y. Sections were then differentiated, dehydrated in absolute ethanol, 
cleared in xylene and mounted. 
Additionally, parallel triple staining of fluorescence EBER-ISH (FISH) and 
immunofluorescence (IF) was carried out: 
1- Deparaffinised and hydrated slides were blocked for endogenous peroxidase 






2- Tissue sections were dehydrated and hybridized with labelled EBER probes. 
Stringency washes were carried out the following day. 
3- Tissue sections were blocked using 5% BSA. 
4-  Three primary antibodies were applied simultaneously; mouse anti-DIG, rabbit 
anti-GFAP, and goat anti-Iba1 at optimized dilutions. Tissue sections were 
incubated overnight at 4˚C, and washed the following day. 
5- Slides were incubated in the dark for 1 hour at room temperature with 
fluorochrome-conjugated secondary antibodies; Alexa Fluor® 488 AffiniPure 
Donkey polyclonal Anti-Mouse IgG (H+L) (Jackson ImmunoResearch, Code: 
715-545-151) diluted at 1:200, polyclonal anti-rabbit- CY5 conjugate and 
polyclonal anti-goat-rhodamine red conjugate diluted as previously mentioned. 
6- Slides were washed, mounted and visualized in a fluorescent microscope.  
Antigen Antibody type (clone) Optimal Dilution 
(titrations tried) 
Source 
EBNA1 Unconjugated mouse mAb IgG1, 
(clone D810H)  
1:10 (1:10, 1:25, 1:50) Thermo Fisher 
Scientific 
BZLF Unconjugated mouse mAb, raised in 
mouse (clone BZ1) 




CD3 Unconjugated mouse mAb IgG1 
(clone PC3/188A) 





CD19 Unconjugated mouse mAb IgG1 
(clone LE-CD 19) 
1:100 ( 1:100, 1:200) Thermo Fisher 
Scientific 
CD20  Unconjugated mouse mAb 
IgG2a,кappa (clone L26) 




DIG Unconjugated mouse mAb (clone 
D1-22) 
1:2500 Sigma 
DIG Alkaline phosphatase conjugate 





GFAP Rabbit polyclonal Z0334 Ig fraction 1:4000 Dako 
Iba1 Goat polyclonal IgG 1:500 Abcam (ab5076) 
 






Chapter 3: Results 
 
3.1 Optimization of DNA Extraction from Formalin Preserved Tissues 
Using traditional phenol-chloroform methodology, genomic DNA was 
successfully extracted from 8 brain slices (5 white matter and 3 meningeal areas). 
Fixation period for these samples ranged between 5 and 16 years. The amount and 
purity of genomic DNA recovered were reasonably good. Mean amount of extracted 
DNA (±SD) was 545±368 ng/µl (range: 177 ng/µl- 1.6 µg/µl) and mean purity 
(expressed as 260/280 ratio) was 1.70±0.2 (range: 1.3-2.0). However, PCR 
amplification of a small fragment of the house-keeping gene human β-globin (104 bp) 
was inhibited in all 8 samples. Positive control DNA extracted from B95-8 cell line 
using the phenol-chloroform method, successfully amplified β-globin fragment, 
indicating that inhibition of PCR observed with brain DNA might be a consequence 
of sample inherent inhibitor. A 100 ng DNA from each of the 8 samples was seeded 
with an equal amount of B95-8 cell line DNA to assess the extent of PCR inhibition. 
The magnitude of PCR inhibiton seemed relatively large, as half of the samples (4 out 
of 8) inhibited PCR amplification of β-globin fragment (figure 3.1).  
 
Figure 3.1: PCR amplification of β-globin (104 bp). DNA from 8 brain samples were 
seeded with 100 ng of positive control DNA at 1:1 ratio. M: 100bp DNA marker, ‘-‘: 
negative control (DNA-free water), ‘+’: positive control (B95-8 cell line DNA), E: 
empty well [275] 
Two of the brain DNA samples that inhibited β-globin amplification (despite 
seeding with the positive control) were seeded with a serial dilution of B95-8 cell line 






(from 100) to 50 ng and seeded with an equal amount of B95-8 cell line DNA. This 
suggested that the magnitude of PCR inhibition might depend on the amount of brain 
DNA used as a template. As the amount of B95-8 cell line DNA serially declined, the 
intensity of PCR signal decreased as well, and the inhibitory effect of brain DNA 
seemed more conspicuous. However, the signal was still detectable at the lowest 
concentration of B95-8 cell line DNA. This indicated that inhibition caused by 50 ng 
brain DNA was minimal but sufficient to cause PCR inhibition of brain DNA on its 
own (figure 3.2). 
 
Figure 3. 2: Seeding brain DNA with positive control. PCR amplification of β-globin 
(104 bp) in 2 brain samples. Seeding 50 ng of brain DNA with a serial dilution of 
positive control (B95-8 cell line) DNA. 1 and1`: 50 ng brain DNA+ 50 ng B95-8 
DNA, 2 and 2`: 50 ng brain DNA + 25 ng B95-8 DNA, 3 and 3`: 50 ng brain DNA + 
12.5 ng B95-8 DNA, 4 and 4`: 50 ng brain DNA + 6.25 ng B95-8 DNA, 5 and 5`: 50 
ng brain DNA + 3.125 ng B95-8 DNA. M: 100 bp DNA marker, ‘-‘: negative 
control, ‘+’: positive control, E: empty well 
To overcome PCR inhibition, different commercial kits for DNA extraction 
were tried. Compared to phenol-chloroform method, DNA extraction kits recovered 
relatively smaller amounts (mean: 20±3 ng/µl), and lower purity (mean 260/280 ratio: 
2±0.2) of brain DNA. PCR amplification of human β-globin was inhibited in most of 










Figure 3.3: DNA extracted using different protocols. PCR amplification of β-globin 
in brain DNA. Samples 1- 8 were extracted using commercial extraction kits. 
Samples 9-13 were extracted using phenol-chloroform method after processing, 
paraffinising and deparaffinising brain tissue. M: 100 bp DNA marker, ‘-‘: negative 
control, ‘+’: positive control, E: empty well 
Because formalin is known to cause inhibition of PCR amplification we tried 
to eliminate as much formalin as possible from brain tissues. During tissue processing 
for paraffin embedding, tissues were exposed to series of dehydration and clearing 
steps. The rationale behind tissue processing was to remove formalin from fixed brain 
tissues, which might help overcome PCR inhibition. Five brain tissues were processed, 
paraffinised, and deparaffinised. Mean amount and purity of DNA extracted from the 
5 samples (using phenol-chloroform method) was 284±150 ng/µl and 1.7±0.1, 
respectively. Despite tissue processing before DNA extraction, inhibition of PCR 
amplification of β-globin persisted (figure 3.3).  
We also tried 3 concentrations of the chelating agent MgCl2 in the PCR 
mastermix to find the optimal concetration that could optimize the activity of Taq 
DNA polymerase and hence PCR amplification. Although 2 mM MgCl2 was efficient 
in amplify positive control DNA, PCR inhibition remained in brain DNA using either 
2, 3 or 4 mM MgCl2. Substituting MgCl2 with Q solution (provided with Qiagen Taq 
PCR), however, reduced PCR inhibition as weak signals appeared in few samples 








Figure 3.4: Using different concentrations of MgCl2. Q solution was added in PCR 
mastermix of 4 samples (1-4). Three of these 4 samples had MgCl2 in PCR 
mastermix of varying concentrations; 2, 3 and 4 mM. M: 100 bp DNA marker, ‘-‘: 
negative control, ‘+’; positive control, E: empty well 
3.1.1 Defining PCR inhibitor(s) 
It was noticed that DNA extracted using phenol-chloroform method contained 
whitish pellet. The white precipitate was thought to be a possible PCR inhibitor, 
potentially related to salted DNA precipitation step. Thus, we substituted sodium 
acetate with sodium chloride. The white pellet was eliminated when DNA was 
precipitated using NaCl, but PCR was still inhibited. 
Beside formalin, several chemicals used during DNA extraction such as SDS 
and chloroform, could be co-extracted and cause PCR inhibition. To reduce DNA 
contamination with formalin, tissues were thoroughly washed in several (6-10) 
changes of washing buffer. Although this improved PCR amplification signal in some 
samples, yet PCR inhibition still existed in most of the samples.  
Moreover, the amount of SDS, an essential detergent to lyse cell membrane for 
DNA extraction, was reduced from 1% to 0.1%. Genomic DNA was extracted from 5 
weight-equal brain samples, and each sample was represented by 2 replicas. One DNA 
replica was extracted using 1% SDS and the second replica was extracted using 0.1% 
SDS, keeping all other extraction parameters fixed. A 10-fold decrease in SDS amount 






with 0.1% SDS showed PCR signal for human β-globin compared to only 3 out of 5 
samples treated with 1% SDS (figure 3.5). 
 
Figure 3.5: Using different amounts of SDS. PCR amplification of 104 bp- β-globin 
(β-G) in 5 weight-equal brain samples, incubated with digestion buffer that contained 
1% or  0.1% SDS.  Other extraction parameters were kept constant. ‘-‘: negative 
control, ‘+’: positive control, E: empty well [275] 
To ensure consistent PCR-amplifiable quality of DNA, a number of positive 
changes in DNA extraction protocol were subsequently implemented:  
1- Thorough washes of brain tissues in 1xPBS, to eliminate the fixative. 
2- DNA precipitation using 0.1 M NaCl. 
3- Using 0.1% SDS in digestion buffer. 
3.1.2 Optimising digestion conditions 
3.1.2.1 Proteinase K concentration  
Other factors that govern DNA quality and quanitiy were revised to obtain the 
best quality DNA from archival formalin fixed material. Proteinase K, an important 
determinant of DNA quality and quantity, digests cellular proteins, nucleic acid-
associated proteins and some DNases [288]. To determine the best concentration of 
proteinase K, 4 weight-equal brain samples (each sample had 5 replicas) were digested 
at 55˚C with 5 different concentrations of proteinase K in parallel incubation setups 
for 24 hours. DNA purity was invariable between tissues digested with different 
concentrations of proteinase K. Highest yield of DNA (111 ng/µl) was recovered when 






the lowest yield (60 ng/µl) was recovered when tissues were digested with the lowest 
concentration of proteinase K (0.15 mg/ml) (figure 3.6 A). PCR-amplifiable quality of 
the extracted DNA was also checked. The best signal of β-globin amplification was 
achieved with DNA digested with 0.62 mg/ml proteinase K. Despite the highest yield 
obtained from tissues digested with 2.5 mg/ml proteinase K, PCR signal was 
comparatively weak (figure 3.6 B). In general, digesting tissues with 0.62 mg/ml 
proteinase K for only 24 hours was sufficient to extract PCR amplifiable DNA with 
mean yield of 67±15 ng/µl (figure 3.6 C). Since a concentration of 0.5 mg/ml (within 
the optimal range of enzyme activity) was previously shown to result in good quality 
and quantity of DNA, it was applied in all the subsequent experiments. 
 
Figure 3.6: Using different proteinase K concentrations. Four weight-equal brain 
tissues were digested with 5 different proteinase K concentrations concurrently. A) 
Mean DNA yield obtained when digesting tissues with 5 different proteinase K 
concentrations (bars). Long standard error bars indicate high variability in DNA 
yield between samples within the same group. The big intra-group variation in DNA 
yield might reflect samples variation in postmortem interval and length of formalin 
fixation, both of which are factors known to determine amount of DNA extracted 
from a given tissue. B) PCR amplification of 104 bp-β globin fragment in the 5 
groups treated with a given proteinase K concentration. C) Mean band intensity of 
amplicons within a same group as semi-quantitatively determined using Image J 






3.1.2.2 Digestion length 
Tissue digestion could also be optimized by regulating the length of digestion. 
Twenty six randomly selected brain tissues were digested with 0.5 mg/ml proteinase 
K at 3 different time lengths (table 3.1). Length of formalin fixation did not vary 
between the selected tissues. In the first group, 8 tissues were digested for 39 hours 
and  produced 106±68 ng/µl DNA. In the second group, 10 tissues were digested for 
68 hours. This longer digestion period resulted in higher DNA yield (mean DNA 
amount was 118±50 ng/µl). Eight tissues in the third group were digested for 116 
hours. DNA yield was highest in this group (mean of 341±132 ng/µl). The purity of 
extracted DNA did not differ between the 3 groups.  
Length of digestion 39 hours 68 hours 116 hours 
No. of cases 8 cases 10 cases 8 cases 
Mean fixation length 11±7 14±8 13±6 
Mean DNA yield 106±68 118±50 341±132 
Mean 260/280 OD 1.60±0.1 1.60±0.05 1.70±0.05 
 
Table 3.1: Properties of DNA extracted from tissues digested at 3 different lengths. 
Mean fixation length in years. Mean DNA amount in ng/µl 
To evaluate DNA quality (i.e. extent of DNA fragmentation), 5 DNA samples 
from each group were electrophoresed on 2% agarose gel. DNA was remarkably 
fragmented, with most of the fragments being less than 200 bp (figure 3.7 A). Tissues 
digested for 68 hours showed better DNA smear pattern compared to tissues digested 
for 39 and 116 hours. Thus, we checked PCR amplifiability of DNA extracted from 
all ten tissues digested at 68 hours using primers for house-keeping genes of 3 different 
lengths (104 bp β globin, 351 bp GAPDH, and 560 bp GAPDH). In consistence with 
DNA gel electrophoresis results, the small fragment, 104 bp β globin, was amplifiable 
in all 10 DNA samples (figure 3.7 B). However, the signal was lost in ~ 1/3
rd  of the 






of the samples could not amplify a fragment that is over 500 bp. Therefore, primers 
flanking small DNA sequence (less than 200 bp) were used to assess both PCR internal 
control and presence/absence of EBV viral DNA in formalin preserved brain tissues. 
 
Figure 3.7: Testing DNA quality. DNA was extracted from tissues digested at 3 
different lengths. (A) Quality of DNA was tested on 5 samples from each digestion 
length group. (B) PCR amplifiability of DNA extracted from ten tissues digested for 
68 hours. M: 100 bp DNA marker, ‘-‘: negative control, ‘+’: positive control, E: 
empty well [275] 
3.1.2.3 Final optimized extraction protocol  
Eventually, genomic DNA extraction from long-term formalin fixed and 
preserved human brain tissues using phenol-chloroform method was formulated into 






1- A small piece of brain tissue was extensively washed in 6-10 changes of 1xPBS 
buffer. 
2- Tissues were homogenized and incubated with a digestion buffer containing 
500mM TRIS, pH 9.0; 20mM EDTA, 10mM NaCl, 0.1% SDS and 0.5 mg/ml 
proteinase K, at 55 °C for 68 hours. 
3- Tissue lysate, then, underwent phenol-chloroform biphasic extraction. 
4- DNA in the upper aqueous phase was transferred to a new sterile tube, and 
precipitated in cold absolute ethanol using 0.1M NaCl.  
5- Precipitated DNA was washed with cold 70% ethanol, air dried, and 
resuspended in TE buffer. 
PCR amplification was further enhanced by using primers flanking small 
fragments of less than 200 bp and adding Q solution in PCR mastermix.  
3.2 DNA Extraction from 1 White Matter and 3 Meningeal Areas 
DNA was extracted from all 122 cases using the optimized conditions of 
phenol-chloroform extraction protocol, from 2 distinct brain areas, white matter and 
meninges. The mean amount of DNA extracted from the white matter  (548±457 ng/µl) 
was comparable to that extracted from the meninges (514±449 ng/µl) (Table 3.2). All 
122 cases had at least 1 replica of meningeal DNA. While 106 cases had 2 replicas, 60 
cases had 3 replicas of meningeal DNA, allowing for investigating multiple regions of 
the meninges (table 3.2). 
Target brain area White matter Meninges 
No. of cases 122 cases Replica1: 122 cases 
Replica 2: 106 cases 
Replica3: 60 cases 
Mean DNA yield 548±457 ng/µl 514±449 ng/µl 







Table 3.2: Properties of DNA extracted from all cases. DNA was extracted from 
white matter and meninges 
Internal PCR control was checked by amplifying human β-globin (104 bp), 
which was amplifiable in all the 122 white matter DNA (figure 3.8 A) and  meningeal 
DNA samples (figure 3.9 A). Meningeal replicas that failed in amplifying β-globin 
were excluded from downstream molecular detection of EBV. 
 
Figure 3.8: PCR amplifiability of white matter DNA. A) PCR amplification of β-
globin in white matter DNA from MS and non-MS cases. β-globin fragment was 
amplifibale in all tested DNA. B) Presence of EBV in the white matter was checked 
by amplifying EBV BamHI W fragment. EBV was detected in 15/26 MS and 0/6 











Figure 3.9: PCR amplifiability of meningeal DNA. A) PCR amplification of β-globin 
in meningeal DNA from MS and non-MS cases [275]. β-globin fragment was 
amplifibale in all meningeal DNA. B) Amplification of EBV BamHI W fragment in 
meningeal DNA from MS and non-MS cases. EBV was detected in 6/23 MS and 0/9 
non-MS DNA. M: 100 bp DNA marker, ‘-‘: negative control, ‘+’: positive control, 
NMS: non-MS case 
3.3 Detection of EBV in White Matter 
The presence/absence of EBV in white matter DNA was checked by 
amplifying a conserved sequence of 152 bp of EBV BamHI W fragment (figure 3.8 
B). Overall, 45 cases (37% of all white matter DNA) were EBV positive in the white 
matter. Forty-two MS and 3 non-MS cases (41% vs 14% respectively) were found to 
be positive. Two of EBV positive non-MS control cases had definitive brain pathology 
(dementia with Alzheimer’s disease and progressive tauopathy) at autopsy. 
3.4 Detection of EBV in Meninges 
With relatively high percentage of EBV positivity in white matter DNA, one 
must understand how EBV could gain access to the brain. PCR amplification of EBV 
BamHI W fragment was checked in multiple replicas of meningeal DNA (figure 3.9 






meningeal replica. Seventeen percent of the cases were EBV-positive in 2 replicas and 
2% were positive in all 3 meningeal replicas. Frequency of EBV positivity in 
meningeal DNA was higher in MS cohort (49/101 MS cases) than in control cohort 
(3/21 non-MS cases). EBV positive non-MS control cases were characterized with 
brain pathologies (meningioma and dementia with Alzheimer’s disease). Overall, 
regardless of whether it was white matter DNA or meningeal DNA, standard PCR 
revealed EBV positivity in 64 MS cases (64%) and in 5 non-MS control cases (24%). 
3.5 Investigating the Presence/Absence of Other Ubiquitous Herpesviruses 
To determine whether EBV presence in the brain was preferential and 
selective, PCR amplification of small conserved fragments from HSV-1, CMV and 
HHV-6 genomes was performed on randomly selected 16 EBV positive white matter. 
Primers for these herpesviruses were chosen based on our finding that DNA extracted 
from archival formalin fixed materials was of poor quality and could only reliably 
amplify fragments of less than 200 bp. Thus, the amplicon size for all three 
herpesviruses was less than 200 bp. All 16 samples showed no signal for either HSV-
I (figure 3.10 A), CMV (figure 3.10 B), or HHV-6 (figure 3.10 C). Few non-specific 
bands were seen in PCR amplification of CMV and HHV-6 fragments from 2 DNA 
samples. Each sample, then, underwent PCR amplification for CMV and HHV-6 
fragments in duplicates, which ultimately were negative for CMV and HHV-6. These 
results suggested that EBV presence in the brain might be selective and less likely a 
result of non-specific influx into the brain, indicating that EBV may have a role in the 









Figure 3.10: PCR amplification of 3 common herpesviruses. 16 EBV positive white 
matter DNA were tested. A) HSV fragment (92 bp) was not detected in the white 
matter. Positive control DNA for HSV-I was extracted from a clinical sample with 
substantial HSV infection. B) CMV 139 bp fragment was not detected in the white 
matter. Positive control DNA for CMV was extracted from a clinical sample with 
heavy burden of CMV infection. C) All 16 DNA samples were also negative for 
HHV-6 137 bp fragment. PCR was repeated for samples that showed non-specific 
bands to confirm the negative results. M: 100bp DNA marker, ‘-‘: negative control, 
‘+’: positive control DNA, E: empty well 
3.6 Quantitation of EBV Load in EBV Positive Cases 
To estimate viral load in EBV positive white matter and meningeal DNA, we 
performed real-time (quantitative) PCR. DNA extracted from Namalwa cells, serially 
diluted in nuclease-free water was used as a standard to quantify EBV copy numbers 







1- DNA was extracted from 1x106 viable cells. This resulted in 11.2 µg DNA, 
equivalent to 89.29 Namalwa cells per 1 ng DNA. 
2- Since Namalwa cells have two EBV copies integrated per cell [280], 1 ng DNA 
(89.29 cells) contained 178.57 EBV copies. 
Five dilutions of Namalwa DNA were used: 1x102, 1x101, 1, 1x10-1 and 1x10-2 
ng/reaction, representing 17857, 1785.7, 178.57, 17.857, 1.7857 viral copies, 
respectively (table 3.3). Using TaqMan real-time PCR amplification of EBV BamHI 
W region, mean Ct values were determined for each Namalwa DNA concentration. 
Subsequently, individual mean Ct values (Y-axis) were plotted against the log EBV 
known copy numbers (X-axis) (figure 3.11). The slope of the linear curve which 








Log EBV copy number 
100 ng/reaction  22.256 8929 17857 4.251808499 
10 ng/reaction 25.108 892.9 1785.7 3.251808499 
1 ng/reaction 28.39 89.29 178.57 2.251808499 
0.1 ng/reaction 33.203 8.929 17.857 1.251808499 
0.01 ng/reaction 35.511 0.8929 1.7857 0.251808499 
 







Figure 3.11: Standard curve for qPCR. The curve was established using Namalwa 
DNA. Five 10-fold serial dilutions of Namalwa DNA (X-axis) were plotted against 
individual mean Ct values (Y-axis). The linear equation: y = -3.4605x + 36.686, R² = 
0.9896 
Using Namalwa standard curve, EBV viral load was quantitated in the brain. 
Amplification that took place at or above mean Ct value of 34 (less than 10 EBV copies 
per 100 ng DNA) were considered very low or undetectable levels. EBV copy number 
was calculated for each test sample using the equation:  
   
EBV copy number = 10  Ct sample – intercept 
                            Slope 
   
Of the 45 white matter DNA samples, 40 had measurable EBV load ranging 
from 16,823 to 157 copies per µg DNA. EBV copy number between 100 and less than 
1,000 copies per µg DNA was considered low viral load, while a copy number between 
1,000 and less than 2,000 EBV copies per µg DNA was considered moderate viral 
load. More than half of the samples had moderate viral load (table 3.4). Only 3 samples 
had more than 2,000 EBV copies per µg DNA, and this was considered relatively high 






copies per µg DNA. The variation noticed in EBV load in the white matter could partly 
be due to varying number of reiteration of BamHI W region (7 to 11 repeats per EBV 
copy; varying between different EBV strains). Also, any potential difference between 
EBV strain in Namalwa cells and that in the brains could possibly affect the precision 
of EBV quantification [138]. However, targeting a sequence that has multiple repeats 
in each EBV genome makes up the great sensitivity of the assay to detect low-level 
EBV. 




Mean EBV load  
Low (100 ≤ EBV copies/ µg DNA < 1k) 16 515 525±279 
Moderate (1k ≤ EBV copies/ µg DNA < 2k) 21 1,248 1,431±320 
High (≥2k EBV copies/ µg DNA) 3 4,927 7,923 ±7,844 
Total  40 1,157  1,556 ± 2,608 
 
Table 3.4: A summary of EBV load in white matter DNA. EBV load: viral copies/ 
µg DNA. Mean EBV load in white matter DNA was expressed as mean ±SD 
Similarly, EBV was quantified in EBV positive meninges (2 and 3 replicas 
were pooled into one 50 ng/µl aliquot). Only one of the 19 meningeal DNA had 
detectable (168 copies/ µg DNA) viral level, suggesting that EBV signal (in 
conventional PCR) might have emanated from occasional EBV-harboring cells, which 
had survived the harsh conditions of DNA extraction. The undetectable viral load was 
consistent with PCR weak bands. 
3.7 Histopathology of MS Lesions 
A total of 358 paraffin blocks from the white matter/ white matter-grey matter 
junction (brain parenchyma), and 257 meningeal blocks (total 615 blocks) represented 
all 122 MS and non-MS cases. Each case had sections stained for histopathological 






based on H&E staining. Tissue abnormalities in non-MS cases that had other 
neurological disorders such as Alzheimer’s disease, Parkinsonism and meningioma 
were confirmed. MS cases showed variable histopathological features, including but 
not limited to mild leptomeningeal inflammation, fibrous sharply demarcated plaques, 
wide-spread perivascular and parenchymal inflammation, gliosis, lipid-laden 
















Figure 3.12 Histopathological features of MS lesions. a) Hypocellular fibrotic lesion 
b) Oedematous lesion with marked myelin vacuolation (arrowhead) adjacent to 
perivenous inflammation c) Widespread perivascular and parenchymal immune 
infiltration. d) Gliosis. e) Intense inflammation in the meningeal layers. f) Multiple 







3.8 Quality Control for EBER-ISH 
EBER-ISH is considered the ‘gold standard’ for localizing EBV infected cells 
in a given tissue, and is often used to visualize the source of EBV positive signal 
obtained with PCR. Sections from 615 paraffin blocks were stained for EBER-ISH. 
For EBV positive control, tonsil tissue from a patient diagnosed with EBV infectious 
mononucleosis (IM) was used. The EBV-IM tonsil paraffin block was a kind gift of 
Prof. Gerald Neidobitek, Institute of pathology, Berlin. Using labelled EBER antisense 
probe, EBER-positive cells were easily spotted in IM tonsillar tissue as abundant 
specific brown nuclear staining cells scattered throughout the tissue (figure 3.13 a). 
EBER-positive cells had small to medium-sized nuclei with characteristic staining-
free nucleoli, and a morphology typical of lymphoid cells (figure 3.15, note at high-
power view). Specificity of EBER-ISH staining was ensured by using EBER sense 
probes, which were non complementary to EBER sequences and hence not expected 
to bind to the target EBERs. Additional negative controls constituted of performing 







Figure 3.13: EBER-ISH on IM tonsil.  a) Low-magnification view showing widely 
disseminated EBV infected cells (scale bar 100µM). b) A closer view at well- 
distributed, easily detectable EBV infected cells (scale bar 50µM). c) and d) High-
power view, note the characteristic nuclear EBER staining (scale bar 20µM) 
 
Figure 3.14: Testing specificity of EBER-ISH. Quality control for specificity of 
EBER probes was confirmed using EBER sense probes. No staining was revealed 
with these negative controls for EBER-ISH. Left panel showing low-magnification 
view (scale bar 50 µM), and on the right higher magnification view (scale bar 20 
µM). Using RNase A treatment prior to hybridization with EBER antisense probes 






3.9 Localization of EBV Infected Cells in the Brain 
Once the quality control of EBER-ISH was ensured, all brain sections from 
both MS and non-MS cases were stained for EBER-ISH. All sections were screened 
carefully under light microscope to avoid missing single positive cell. For analysis 
purpose, EBER-positive cells were counted manually in EBV-positive sections (mean 
dimension 1.5 x 1 cm). In sections representing brain parenchyma, EBER-ISH 
revealed positivity in 80/101 MS cases and in 5/21 non-MS cases. While in meningeal 
sections, positivity was found in 60 MS cases and in 3 non-MS cases. In total, 83 MS 
cases (83%) and 5 non-MS cases (24%) were positive for EBV by EBER-ISH. 
Correlation between EBV positivity and type of MS, age at death, sex, and disease 
duration could not be established due to lack of available data. In non-MS control 
tissues, however, EBV positivity was mainly in cases with documented neurological 
disorders (meningioma, dementia, and progressive supranuclear palsey-like 
Tauopathy). Also, in most cases EBER positivity was seen in lymphocyte-like cells. 
Occasionally, EBER positive cells with morphology not typical of lymphocytes were 
also seen (figure 3.15 -3.18).  
Positivity for EBV in the white matter was categorized into 3 categories; ‘+’ 
for sections containing 1-49 positive cells, ‘++’ for sections containing 50-200 positive 
cells, and ‘+++’ containing over 200 positive cells. Forty MS cases were categorized 
as ‘+’, 29 MS cases as ‘++’ and 19 MS cases as ‘+++’ (heavily infected cases). It is 
noteworthy that the MS case which had the highest viral load as determined by qRT-
PCR, was also amongst the cases which had the highest number of infected cells by 






found to be EBV positive. Furthermore, meninges from this case was also found to be 
EBV positive (see ahead). 
 
Figure 3.15: EBER-ISH on case MS95. EBV infected cells were localized in brain 
parenchyma, which showed ‘++’ positivity (using antisense probe). Sections from 
the same case hybridized with EBER sense probe gave negative signals. Original 
magnification 40x 
 
Figure 3.16: EBER-ISH on case MS17. EBV infected cells scattered (++) in brain 
parenchyma in a case of severe MS with chronic inactive lesions. Using EBER sense 
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Figure 3.17: EBER-ISH on case MS63. This case represented RRMS with 
predominance of chronic inactive lesions. This case showed wide distribution of 
EBER positive cells (heavily infected case). These cells resided adjacent to/ part of 
perivascular infiltration and parenchymal inflammation. Positive signals were 
eliminated using EBER sense probe. Original magnification 40x 
 
Figure 3.18: EBER-ISH on case non-MS21. EBER signal was seen in this control 
case (meningioma case), showing positivity in lymphocyte-like cells and other 
morphologically distinct cells. Using sense probe ensured staining specificity. 
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3.10 Determining Entry Route of EBV into the Brain 
Several reports have discussed the role for the immunopathology of meninges, 
particularly meningeal inflammation in the pathogenesis of different stages of multiple 
sclerosis [289-293]. Meninges were investigated as a potential route of EBV and 
stained for EBER-ISH. In many MS cases, meninges had little or no cellular 
component and only fibrous connective tissue could be seen. Similarly, control cases 
lacked any visible inflammation. Therefore, positive signals for EBERs were hardly 
detectable in such sections. 
EBER-ISH revealed positivity in lymphocyte-like cells infiltrating the 
meninges in at least one replica in 60/101 (59%) MS cases where mild to moderate 
meningeal inflammation was observed. In the non-MS control cohort, 3 cases (14%) 
which were found positive for EBERs in brain parenchyma, were also positive for 
EBERs in the corresponding meningeal sections (figure 3.19). It was commonly 
noticed that EBERs positivity in the meninges corresponded to that in brain 










Figure 3.19: EBER-ISH on MS meninges. Case MS47 was used as a representative 
for EBER positivty obtained in inflamed the meninges (a and b). EBER sense probe 
was consistenly used to ensure signal specificity (c). Original magnification of low-
power view 10x, and high- power view 40x 
3.11 Correlating EBV Positivity in the Brain Using PCR and ISH 
Utilizing two different techniques in detecting EBV in two different regions of 
the brain provided strength for the obtained data, because each technique has -to some 
extent –compensated for the limitations of the other one. The following conclusions 
have been drawn from the overall data: 
1- Taken all together, both techniques revealed positivity in 90% of MS cases vs 






2- EBER-ISH appeared more sensitive than PCR, because EBER-ISH revealed 
positivity in 83% MS cases, while PCR data showed positivity in 64% MS cases. 
Fivty seven of these cases were found positive by both techniques (figure 3.21). 
3- EBV positivity was found to be higher in brain parenchyma than in meninges 
(87% vs 80% respectively). Seventy-seven percent of MS white matter was found 
EBV positive by both techniques (figure 3.22). 
4- Assessing the sensitivity of each technique in each brain region, EBER-ISH was 
found more sensitive than PCR in detecting positive signals in brain parenchyma 
(79% vs 41% respectively). Less dramatic difference between the techniques was 
seen in the meninges; as positivity revealed by ISH was 58% compared to 49% 
by PCR (figure 3.23). 
 
Figure 3.20: EBV prevalence in MS and control cases. EBV positivity in MS cohort 
(right) and non-MS control cohort (left) was revealed by PCR and ISH. Ctrl: control 







Figure 3.21: EBV positivity in MS cohort revealed by PCR and ISH 
 
Figure 3.22: EBV positivity in two regions of the MS brain. WM: white matter, M: 
meninges 
 
Figure 3.23: Sensitivity of PCR and ISH. Detection power of the techniques was 






3.12 Optimization of Antigen Retrieval  
In order to obtain the most sensitive and specific signals for the detection of 
viral and cellular antigens using immunohistochemistry (IHC), multiple approaches of 
antigen retrieval were tested. Untreated sections from both tonsil control tissue and 
brain tissues gave false negative signal for both cellular and viral proteins. Heat-
induced antigen retrieval was tried using pre-boiled sodium citrate (pH 6.0) buffer 
[294] in a domestic microwave [283, 295], for different time lengths [296]. IHC 
staining signal was not detected in control tissues heated for 3 minutes, while heating 
for continuous 10 minutes resulted in background and several non-specific staining in 
brain tissues. These problems were less severe in control tonsil tissue, because it was 
not exposed to over-fixation in formalin. Using two 6 minute-cycles of heating, 
antigens were well-retrieved in control tissues (figure 3.24) but background and non-
specificity persisted in brain tissues. Using 3 cycles of heating, each for 3 minutes, 













Figure 3.24: Effect of heating on antigen retrieval. Comparing the effect of 
continuous and discontinuous heating was performed on control tissue (human 
tonsil) incubated in sodium citrate buffer (pH 6), exposed to high-power microwave 
heating for either a) continuous 10 minutes or b) 2 cycles each for 6 minutes. 
Discontinuous pattern of microwaving was found to produce enhanced crispness of 
CD3 staining in the tonsil. Original magnification 40x 
We substituted microwave heating with heating on hot plate. Using hot plate 
at high temperatures (150-200 ˚C) eliminated the problem of detachment of brain 
tissues that might be due to microwave irradiation. Although this method of heating 
gave good staining in control tissue, staining in brain sections was dull and inconsistent 






Moreover, we compared two different pH points of antigen retrieval buffer, pH 
6 and pH 9 (Tris-HCl buffer). Using basic buffer together with heating on hot plate led 
to a better staining pattern in brain tissues, which was enhanced by increasing the 
heating period to 20 minutes. Thus, antigen retrieval for immunohistochemistry for 
cellular and viral antibodies that we used was optimized by heating sections: 
1- in basic buffer (Tris-HCl, pH 9.2), 
2- on a hot plate at high temperatures 150-200˚C, and 
3- for 20 minutes. Note that this long exposure to high temperature caused buffer 
evaporation so continuous adding of the buffer was required to ensure levels that 
covered tissue sections. 
3.13 Determining EBV Gene Expression in MS Brain 
The presence of EBV in a large proportion of MS cases suggested that virus 
may be involved in the pathogenesis of this disease. To further address this, we wanted 
to determine what viral genes were expressed in infected cells. We stained two 
important EBV genes, the latent antigen EBNA1 and the immediate early gene BZLF1. 
The expression of BZLF1 marks the switch from latency to lytic cycle. The quality 
control of immunohistochemistry was checked using tonsillar tissue from IM case and 
agarose-embedded B95-8 cells. Specificity of the staining was validated using 
negative controls (omitting primary antibody) for each section.  
The distribution of EBNA1 staining in IM tonsil section showed a similar 
pattern of distribution to that seen with EBERs staining (figure 3.25). Unlike EBNA1, 
BZLF1 expression was scarce, so spotting BZLF1 positive lymphocytes in a mesh of 






8 cells as a control section for BZLF1 expression proved to be a better control since 
single BZLF1 positive cells could be easily seen (figure 3.26).  
 







Figure 3.26: BZLF1 expression in B95-8 cells. Replication permissive B95-8 stained 
for BZLF1 showed a small percentage of scattered nuclear-stained cells 
Eighteen MS brain sections with heavy EBV infection (>200 EBER positive 
cells) were immunostained for EBNA1 and BZLF1. EBNA1 expression was easier to 
detect in brain parenchyma compared to that of BZLF1. Cells expressing EBNA1 
ranged in number from 5-19 cells per section (~1-10% of EBER positive cells). 
EBNA1 expression was seen in 14/18 brain tissues. Distribution of EBNA1 positive 
cells was diffuse, scattered and almost associated with hypercellular parenchyma 







Figure 3.27 Expression of EBNA1 in case MS55. Original magnification 40x and 
60x 
 
Figure: 3.28 Expression of EBNA1 in case MS63. This RRMS case had higher 
expression of EBNA1 with 18 small lymphocyte-like cells. Original magnification 
40x and 60x 
On the other hand, the level of expression of BZLF1 in the brain tissue was 







suggesting minimal lytic cycle activity (figure 3.29). The almost global absence of 
BZLF1 signal from MS brains does not necessarily translate into lack of lytic cycle in 
EBV heavily infected brain tissues, but it could reflect, among other potential reasons, 
the negligible level of lytic cycle resulting in missed signal. It might also be due to a 
possible association between viral lytic cycle and particular type of MS lesions. There 
was insufficient data to establish a correlation between EBV gene expression and 
disease type or lesion activity. 
 
 






3.14 Phenotypic Characterization of EBV Infected Cells 
After characterizing EBV gene expression in the brain using 
immunohistochemical (IHC) staining, we aimed at characterizing immunophenotype 
of EBER positive cells. Distribution and frequency of two prominent contributors to 
the immune influx in MS brain, CD3 positive T cells and CD20 positive B cells were 
determined using IHC in heavily infected cases. The quality control for CD3 and CD20 
immunostaining was ensured by including human tonsil control tissue (figure 3.30). 
Consistent with autopsy reports, there was an almost universal absence of 
CD19, CD20, and CD3 positive cells in brain parenchyma. Three of the 18 heavily 
infected cases tested had visible infiltration of CD3 positive cells and CD20 positive 
cells. Limited levels of expression of CD3 and CD20 were found in 2 of these cases, 
while widespread distribution of CD3 and CD20 was seen in the third case (RRMS) 
(figure 3.31). Substantial expression of these markers were found within brain 
parenchyma and around blood vessels (perivascular cuffs). Although H&E staining 
showed marked lymphocytosis and gliosis in nearly all of MS sections, many of these 
cells which had indeterminate phenotype. Thus suggesting that EBV might be 
localized in other distinct phenotypically characterized cells such as microglia, 















Figure 3.30: Quality control for CD20 and CD3. Immunostaining IM tonsil tissue 
showed distribution of CD20-positive B cells (making up germinal centre) (a), and 







       
Figure 3.31: Expression of CD3 and CD20 in case MS63. The majority of small 
lymphocyte-like cells stained for CD3 (a and b) and to a lesser extent CD20 (c and 
d). Original magnification 10x (a, b), scale bar 100µM (c), original magnification 
20x (d) 
 
Because of the heavy infiltration of CD20 positive cells in case MS63 (figure 
3.31), we used this case to double-stain for EBERs and CD20. Double staining was 
validated in IM tonsil section (figure 3.32). EBER-ISH in this case showed over 200 
positive cells in a series of sections. However, the number of EBER positive cells seen 
in double staining for EBER and CD20 was very limited (figure 3.33). This could be 
due to reduced sensitivity of one-step ISH compared to two-step EBER-ISH. While 
several cells were found co-expressing EBERs and CD20 (figure 3.34), some had 









Figure 3.32: Quality control for double staining. CD20 IHC and EBER-ISH in IM 
tonsil showed co-localization of CD20 (membrane) brown signal and EBERs 
(nuclear) dark blue signal in many cells. (a) Low-power overview, scale bar 50µM. 









Figure 3.33 Double staining in case MS63. (a) Individual staining of CD20. (b) 




















Figure 3.34: High power view of double staining in case MS63. Membrane CD20 
(brown) and nuclear EBER (dark blue) staining scattered in brain parenchyma. 
Original magnification 40x 
We also stained for both EBERs and Iba1 (a marker for microglia) in this case 
(MS63). Despite the large number of Iba1 positive cells, no evidence for co-expression 
of EBERs was seen (figure 3.35). To furthur examine the phenotype of EBV infected 
cells, we triple-stained for EBERs, Iba1 and GFAP (astrocytes marker), using 
fluorescence in situ hybridization (FISH) and immunofluorescence (IF). IF staining 
was validated for both cellular markers (Iba1 and GFAP) in case MS63 (figures 3.36 








Figure 3.35: Double staining of EBERs and Iba1 in case MS63. This case had gliosis 
but no EBER co-expression. Occasional cells appeared double positive for EBERs 
and Iba1. Original magnification 40x (a), 60x (b) 
 
Figure 3.36: IF staining for Iba1 in case MS63. Iba1 marker does not discriminate 
between monocytic blood-originated macrophages and CNS-resident activated 












Figure 3.37 IF staining for GFAP in case MS63. Abundant astrocytes with elongated 
star-shaped projections. Some astrocytes are in contact with blood vessels. Beside 
tight junctions and perivascular macrophages, astrocytes feet help maintain BBB 
integrity 
Using triple staining for EBERs (green), GFAP (blue) and Iba1 (red) in MS 
brain tissue showed numerous round Iba-1 and star-like GFAP positive cells (figure 






be due to the long fixation, making detection of specific signals a challenging task. 
Further studies are needed to determine whether EBV may infect microglia and 
astrocytes in MS brain. 
 
 






Chapter 4: Discussion 
"If you are asking the wrong question, or the right question in the wrong way, the 
answer doesn't really matter."  -Thomas Pynchon 
The history of research done on determining what causes MS is long, and 
various possible etiological agents have been implicated. MS is a complex polygenetic 
disease that is associated with a number of intrinsic and extrinsic (environmental) risk 
factors [77]. While controversies concerning an association between EBV and MS 
have been around for over 3 decades, the virus continues to be the most strongly 
associated risk factors for MS. The aim of this study was to verify and the delineate 
role of EBV, if any, in MS pathogenesis. Association studies are complex and require 
large sample size to draw valid conclusions. To meet this expectation, coronal brain 
slices from autopsied 122 MS and non-MS control cases were used.  
This thesis brought to light a number of potential technical solutions to 
challenges in using tissue bank formalin archived brain slices. Thus, maximizing 
research benefit from such material. Moreover, multiple aspects of the association 
between EBV and MS were explored and results highlight potential contribution of the 
virus in MS pathogenesis. 
4.1 Maximizing Utilization of Long-Term Formalin Preserved Brain Tissues 
Here we demonstrated that PCR inhibition could be overcome by using 
optimized conditions of extraction. Our findings have confirmed results of previous 
studies, which reported possible extraction of DNA of usable quality despite prolonged 
fixation in formalin -for over 20 and even 40 years [298-303]. Interestingly, some 






are over 400 bp long [300, 301]. Others on the other hand, reported amplification of 
much smaller fragments [298]. 
While we have showed that using SDS in a concentration as low as 0.1% is 
still effective in disrupting tissue homogenate and yet does not inhibit PCR as seen at 
higher concentration (1%), others have suggested that SDS retains PCR inhibition even 
at concentrations as low as 0.01% [304]. This difference could probably be due to 
different tissues used. Nevertheless, early reports recommend using 1% SDS in 
phenol/chloroform extraction of DNA from long time formalin fixed materials [303].  
Another technical challenge emerged when using IHC. Formalin fixation 
induces extensive protein cross-linking [270]. This causes masking of certain epitopes, 
thus impeding immunorecognition by primary antibodies [305]. To enhance 
immunoreactivity we optimized heat-induced antigen retrieval, taking into 
consideration heating temperature, length of heating, and pH of antigen retrieval 
solution. Although the mechanism of action of heat/pH-dependent antigen unmasking 
is not fully understood, several reports have suggested using both high temperature 
and high pH for formalin stored tissues [296, 305-307]. This is believed to promote 
reversal of chemical modification of proteins caused by fixation. This also involves 
protein inactivation and alteration of protein configuration, all of which lead to 
releasing protein epitopes and increasing tissue antigenicity and thus 
immunorecognition of target proteins [296, 305-307].  
4.2 EBV is More Prevalent in MS than in Non-MS Cases 
Our hypothesis that EBV may contribute to MS pathogenesis was tested, by 
investigating EBV presence in the brain tissue of MS and non-MS cases. Two highly 






large series of cases. Both methodologies pointed towards higher prevalence of EBV 
in MS cohort than in controls (90% vs 24% respectively). EBV detection by PCR 
depended on amplifying BamHIW fragment, whereas EBER-ISH, the ‘gold standard’ 
[156] and widely utilized approach in detecting EBV, targeted abundantly expressed 
viral non-coding RNAs. In our hands EBER-ISH showed greater detection sensitivity 
compared to PCR (83% and 64%, respectively). The lower sensitivity of PCR is most 
probably due to poor quality/ quantity of DNA extracted from long-term formalin fixed 
tissues. Hence, using both techniques helped in decreasing false negatives and 
confirming results. 
We further focused on the differential prevalence of EBV in brain parenchyma, 
and we found overall EBV positivity in MS brain parenchyma reached 87.1% as 
opposed to 23.8% in non-MS control cases. It is noteworthy that EBV was detected in 
non-MS control cases which had neurological diseases including progressive 
dementia, Alzheimer’s, progressive supranuclear palsey-like tauopathy, and 
meningioma. EBV was absent in brain tissues from non-MS control cases with no 
history of neurological conditions. This observation confirms results of two previous 
studies where EBV infected cells were seen in the brain of control cases with 
neurological conditions namely those with marked neuroinflammation (stroke), brain 
lymphomas, meningitis and tuberculous meningoencephalitis [266, 308]. Moreover, 
the number of infected cells in these cases was very low, often less than a dozen cells 
[266, 308]. Whether EBV is universally triggered in CNS inflammation associated 
conditions remains to be proven. 
Similar to the pattern observed in our EBER positive cases, Tzartos and co-






and in perivascular cuffs [266]. This distribution specifically correlated with elevated 
expression of inflammatory cytokine IFN-α [266]. Therefore, associating EBV 
infection to specific anatomical pathology, requires further investigation of markers 
associated with MS pathology, including mitochondrial exhaustion and oxidative 
stress [309, 310], complement activation [45], disrupted blood-brain barrier (BBB) 
[48, 311, 312], oligodendrocyte damage, and demyelination and remyelination [57, 
313, 314], and the correlation of these markers with EBV infection.  
Quantitatively, we detected EBV viral load in MS brain parenchyma with copy 
numbers that varied between 157 to 16,823 EBV copies per microgram DNA, with 
approximately 93% of the cases having a viral load below 2,000 copies per microgram 
DNA. Thus, EBV viral load is rather low to moderate in MS brain parenchyma. As 
mentioned above, these viral copy numbers could be partly affected by the quality of 
DNA used. In contrast to this observation, Torkildsen and colleagues [315] reported 
lack of quantitative evidence of EBV presence in MS brain. They suggested the need 
for techniques with greater sensitivity to avoid false negatives due to limited number 
of infected cells present in MS brain tissue that could be easily lost during tissue 
processing for DNA extraction [315]. A potential reason for the discrepant findings is 
that Torkildsen’s study quantitated transcripts of EBNA-1 and -2, LMP1 and BZLF1 
using qPCR as well as IHC for EBNA and LMP in order to conclude EBV presence 
or absence in the brain. Studies on EBV infection biology emphasizes that EBV 
infection could be reliably determined based on detecting EBV genome using sensitive 
methods [275] or abundantly expressed EBERs using EBER-ISH [156]. Therefore, 
targeting other transcripts, the expression of which may or may not occur in certain 






evidence of EBV presence in MS lesions [268, 269]. These studies used a small 
number of cases (12- 20 blocks) to examine their hypotheses [268, 269]. In this study, 
we have used 615 blocks from over 120 MS and non-MS cases to compensate low 
statistical power in the previous studies.  
We also tested the possibility that EBV prevalence in MS brain may be non-
specific, by screening for other common herpesviruses, namely HSV, CMV, and 
HHV-6. Our data clearly indicates that EBV presence in MS is specific and selective, 
since none of the other viruses examined were found in MS cases by PCR. A previous 
study, however, reported the coexistence of EBV, HSV, HHV-6 and VZV DNA in MS 
lesions [316]. EBV DNA was found only in ∼10% of MS lesions and other 
herpesviruses were more prevalent in MS compared to EBV [316]. The authors 
concluded that none of these herpesviruses could be specific for MS pathogenesis 
[316, 317]. This study relied solely on PCR amplification of DNA from MS lesions, 
and no other confirmatory independent tests were done. 
4.3 EBV May Use Multiple Routes of Entry to the Brain  
Compared to brain parenchyma, meningeal layers showed both less prevalent 
and weaker EBV load using PCR and EBER-ISH. Histology and EBER-ISH staining 
showed lack of meningeal inflammation in most of the cases. However, we did find 
evidence of EBV infection in sections with pronounced meningeal inflammation, but 
we could not localize ectopic B cell folicles which were repeatedly reported by Serafini 
et al [263, 265, 308]. Similar to our findings, Kooi et al [290] reported lack of 
widespread inflammation and/or tertiary lymphoid structures in meningeal layers 
[290]. These finidings could be explained by an observation made by few other studies 






lymphoid-like structure in MS (figure 4.1) [289, 291, 293]. These studies reported 30- 
40% incidence of tertiary structures, commonly found in the deep sulci of the forebrain 
from secondary progressive and primary progressive MS cases. Whereas cerebellar 
meninges, particularly subarachnoid space (SAS), had mild chronic 
microglia/macrophage inflitration lacking lymphoid-like structures [289, 291, 293]. 
The degree of dissimination of immune infilitrates from meningeal layers was 
determined by presence of tertiary lymphoid like structures and it appeared to impact 
microglia activation and formation of cortical demyelinative lesions. Thus, athors 
concluded the participation of meningeal inflammation in MS grey matter injury and 
atrophy, which is aggravated by presence of tertiary lymphoid structure [289, 291, 
293]. 
 
Figure 4.1: Immune cells in the brain. These cells buildup in white matter 
perivascular spaces (A) and meningeal SAS [318] 
While embryological growth of  B cell follicles generates anatomically static 
entities, namely secondary lymphoid follicles including several lymph nodes and 
spleen, tertiary lymphoid follicles result from long-standing inflammation within 
certain organs following aberrant tissue-specific autoimmune response. These tertiary 
lymphoid structures, also known as B cell ectopic lymphoid follicles, have been seen 






erythematosus and MS [318]. Based on immunostaining properties, tertiary lymphoid 
structures are described as aggregation of chiefly CD20 positive B cells [308] and a 
collection of other immune cells including Ig positive and/or CD138 positive plasma 
cells, CD35 or CXCL13 positive follicular DCs, ki67 positive proliferating cells, and 
CD3 positive T cells  [318].  
These aggregates exhibit characteristic germinal centre-like properties 
including B cell expansion, differentiation into Ig producing plasma cells, and 
abundance of folliclur DCs with specialized chemokine expression. What does not 
give them a perfect germinal centre feature is absence of mantle zone and prevalence 
of memory B cells and naturally occurring site [319]. Frequently reported CNS sites 
for these germinal centre-like B cell aggregates are leptomeningeal SAS within deep 
cerbral sulci and perivascular cuffs [265, 289, 308, 318, 319]. They may also occur at 
lower frequency within inflamed brain parenchyma, but not within demyelinated or 
chronic active lesions [318].  
It should be noted that CNS tertiary lymphoid structures have been reported in 
particular anatomical sites of the brain, such as cingulate and precentral gyri in the 
frontotemporal, parietal and insular cortex. Also absence or rarity of tertiary structures 
was reported in certain sites including external or inferior brain surface, cerebellum, 
periventricular regions, brainstem and spinal cord [318]. We however, sampled 
meningeal tissues from randomly selected areas, and with no pre-determined 
preference to any specific regions. Our samples (coronal brain slices) were highly 
heterogenous and represented a wide array of brain regions, different age at both 
disease onset and death, gender, MS type and lesion type. These factors could justify 






delicate nature of meninges necessitate gentle cutting during tissue sampling and 
cautious treatment in paraffin blocking and staining. Therefore, we cannot eliminate 
the possibility of false negative in some of our cases resulting from inevitable harsh 
procedures. 
Although it was suggested that B lymphocyte-rich tertiary lymphoid structures 
within meningeal layers could be the main territory of EBV persistence and 
reactivation contributing to MS pathology, [262, 319], we could not demonstrate that 
meninges were the exclusive route of EBV entry to the brain. The majority of 
meningeal blocks were devoid of substantial immune infiltrate within intact meningeal 
layers. Hence, in addition to inflammed meninges, EBV could probably take various 
routes to the brain. We noted EBV infected cells within or in close proximity to 
inflamed perivascular cuffs [264]. Although this was not preferential, BBB endothelia 
could potentially be a divergent route for EBV to utilize in reaching its destination, the 
inflammed brain. This notion is supported by reports demonstrating that human brain 
microvascular endothelia is permissive for EBV infection [320]. We, however, did not 
furthur explore the likelihood of EBV entry via BBB endothelium, so it remains a 
possibility that requires furthur investigation. It is worth asking whether EBV infected 
cells transmigrating across the endothelial layer triggers an immune response by 
cytotoxic CD8+ T cells, as seen within meningeal ectopic structures and contributes 
to cortical plaques genesis. 
4.4 EBV Can Maintain a Latent Infection or Induce a Lytic Cycle in the Brain 
We divided our cases into 3 categories based on number of EBV positive cells. 
While majority of the cases (40 cases) had between 1 to 49 positive cells, 29 cases had 






(over 200 positive cells). It has been shown that detecting EBV latent nuclear protein 
EBNA1 and early lytic BZLF1 requires at least 0.01% to 0.1% EBV infected cells 
[315]. Thus, we immunostained heavily infected cases to capture a global view of the 
nature of EBV infection in MS brain. While some studies have not found evidence of 
lytic or latent infection [315, 321], our results suggested that a proportion of EBV 
infected cells undergo lytic, (defined by BZLF1 immunoreactivity) and latent 
(manifested by EBNA1 immunostaining) infection.  Consistent with our findings is 
the results of several independent studies [262, 264-266]. Recently it was shown that 
EBV infection of human brain microvessel endothelial cell lines was accompanied by 
the expression of a limited set of latent and lytic genes, including BZLF1 and EBNA1 
[320]. We found that EBNA1 expression was more common (~78% vs ~17% of tested 
cases) and higher (~1-10% of EBER positive cells vs ≥ 1%) than BZLF1 expression. 
Earlier reports demonstrated dominance of latency type II phenotype in MS brain by 
showing increased immunoreactivity for LMP1 and LMP2A, and less frequently for 
EBNA2 [264]. We also noted increased cellularity in parenchymal regions containing 
EBNA1 expression. This hypercellularity could be an immune response triggered by 
observed viral gene expression. We suggest that cases showing notable expression of 
lytic genes could experience infiltration of cytotoxic CD8+ T cells. Some earlier 
reports have indicated EBV lytic cycle provokes disturbed immune response, 
particularly from perforin- and granzyme B-secreting cells [262, 264, 265]. 
4.5 Beside B Cells, EBV May Infect Some CNS-Resident Cells 
Apart from occasional cells, we were not able to find broad infiltration of CD3 
positive and CD20 positive cells in most of the brain sections heavily infected with 






of another recent study [315]. We did however find presence of increased CD20 
positive cells in one case where inflamed perivascular cuffs dominated. Others 
reported notable infiltration of CD20 positive cells into brain parenchyma as well as 
within meningeal layers [319, 322].  These studies reported marked presence of B cells 
particularly in progressive MS brain. This clinical type of MS could be under-
represented in our study. Also, it may be possible that B cell population in our samples 
had long-lasting plasma cell phenotype, which are CD20 negative [323].  
Correlating the number of EBER positive cells with CD20 positive cells, we 
found that number of cells stained for EBERs was much higher than that of cells 
stained for CD20. This indicated that despite low infiltration of B cells in brain 
parenchyma, EBV infected cells were conspicuously present. We further confirmed 
these findings by staining for both markers, CD20 and EBERs. Some cells co-
expressed both markers, but others were single positive for either CD20 or EBERs. 
This meant that EBV infection could potentially occur in other types of cells. 
Previously it was shown that EBER positive cells in the brain accumulated in IFN-α 
secreting microglia [266]. We stained for microglia, astrocytes markers and EBERs, 
but our results were not conclusive. This, however, does not eliminate the possibility 
of EBV infecting other types of cells in MS lesions. It has been suggested that a link 
between CNS microglia, EBV and human endogenous retroviruses W family and MS 
associated retroviral elements (HERV-W/MSRV) exist in triggering oligodendrocytes 
injury in MS [125, 130, 324, 325]. Increased expression of these retroviral elements, 
particularly env protein within microglia or astrocytes is thought to be instigated by 






Furthermore, BAFF, a member of TNF family contributing to maintaining B 
cell survival, has been shown to be produced in MS lesions by astrocytes (analogous 
to stromal cells in lymphoid tissues), and induce longevity of CNS infiltrating B cells 
and plasma cells that express BAFF marker [326]. This indicates an intimate 
interaction between astrocytes and B cell (figure 4.2), which could be infected, and 
raises questions regarding EBV spreading to these astrocytes [326]. 
 
Figure 4.2: Close interaction between astrocytes and plasma cells. This interaction 
supports maintenance of long-lived B cells in MS lesions influenced by different 
chemokines and cytokines [326] 
4.6 Proposed Mechanism for the Contribution of EBV in MS Pathogenesis 
Several hypotheses have been proposed to explain potential mechanisms that 
EBV may use to precipitate autoimmune response. These mechanisms include epitope 
spreading, molecular mimicry or cross-reactivity between EBV antigens and self-
antigens, EBV-induced immortalization of ‘encephalitogenic’ B cells that secrete CNS 
antigens-reactive antibodies and present CNS antigens to encephalitogenic T cells, IM-
induced activation of EBV-specific T lymphocytes causing bystander damage to CNS 






hypothesis has yet proved perfect to explain all identified pathological aspects of the 
disease.  
The strong sero-epidemiological evidence linking EBV to MS, which is not 
seen with other viral agents points to genuine contributory link to MS. If EBV infected 
cell infiltration to the brain was a sequelae of hyper-immunity accompanying MS 
inflammation, we would have seen an evidence of infiltration of other human 
ubiquitous viruses into the brain, which we could not demonstrate in here. Also reports 
of developing MS in patients with history of infectious mononucleosis (IM) indicates 
that EBV is not a passive bystander in MS but actively participates toward MS genesis 
[235]. Based on previous findings in line with our results, we propose the following 
events for a role of EBV in MS pathogenesis. 
1- IM and MS risk associated alleles polarize the immune response toward 
inflammatory phenotype, and unstable response from EBV-specific lymphocytes 
that partially lose control of EBV regulation, hence the elevated levels of anti-
EBNA immune response preceding MS onset [240]. Due to EBV immortalization 
of B cells, and deficient antiviral CD8+ T cells response, EBV triggers a 
longstanding dysregulated immune response. 
2- In molecular mimicry, epitopes of EBV antigens are believed to share common 
structure to CNS antigens. Thus, EBV-specific lymphocytes can recognize CNS 
antigens and mount autoimmune response. EBNA1 has been shown to share 
homologous structure to myelin antigens. Through molecular mimicry EBV could 
induce development of CNS antigens-reactive lymphocytes, which through 
transiently disrupted BBB and in response of various chemoattractants, 






3- EBV infected B cells breach BBB with other brain-infiltrating lymphocytes. 
During this immune trafficking event, EBV infects a fraction of endothelial cells 
of brain small blood vessels probably stimulating secretion of more 
chemoattractants and cytokines for additional chemotaxis. 
4- Our results suggest that EBV infection may also involve some CNS-resident cells 
such as microglia and astrocytes. If that is the case, then EBV infection can induce 
these cell to secrete chemoattractant soluble factors into SAS and intrathecal 
compartment causing influx of wide array of lymphocytes into meningeal layers 
forming tertiary lymphoid structures, which in turn participates in subpial cortical 
demyelination. Infecting microglia could also induce their activation and 
subsequently participate in endogenous injury to nearby oligodendrocytes and loss 
of axons [57].  
5- Within the brain, EBV could activate specific sequences of HERV-W/MSRV in 
situ to further contribute to MS pathology.  
4.7 Concluding Remarks, Limitations, and Future Research 
In conclusion, the extensive study in this Masters thesis highlighted several key 
findings: (i) EBV infection preferentially occurs in MS lesions, and may 
fundamentally contribute to the inflammatory nature of the disease, (ii) besides 
meningeal route, EBV may exploit other disrupted routes to access the inflamed brain, 
(iii) EBV infection tends to induce latent cycle more frequently than lytic cycle, but 
this may primarily depend on lesion type as suggested by earlier studies [263, 264] 
and (iv) there is an indication of EBV infection occurring in cells other than typical B 
lymphocytes. We suspect some CNS-resident cells may be involved.  By providing 






frequencies that are higher than to be just an arbitrarily coincident finding, the case-
control study in this thesis adds to the growing body of evidence and supports a 
contributory association between EBV infection and MS pathogenesis.  
Since some studies failed to find an association between EBV and MS, a 
number of potential reasons could cause the discrepant findings reported by different 
studies. Most of these studies used a small number of cases. Reproducibility of studies 
outcome is highly dependent on sample size [328], and type II error are likely to occur 
in small sample size studies. Thus, screening large number of cases, where every single 
case is represented by multiple blocks and many series of sections (figure 4.3), could 
in part reduce inter-studies variability.  
 
Figure 4.3: EBV infected cells in MS brain. Previous reports suggested specific 







Moreover, inconsistencies in tissue processing and means of viral detection and 
sensitivity of the methodologies employed, could greatly influence the results [308]. 
In this study we targeted EBV small non coding RNAs (EBERs) to localize EBV 
infected cells in MS brain. EBERs are expressed in substantial amounts, up to 107 
copies per infected cell. EBER2 expression is ten folds less than EBER1, however both 
are expressed in all latently infected cells [138]. Thus, designing probes that 
specifically target both EBERs together rather than targeting only single EBER 
increases the sensitivity of EBV detection approach [156]. Because EBERs are not 
expressed during viral replication [330], to determine occurrence of EBV lytic 
infection, lytic antigens should be targeted, for instance by immunostaining or using 
reverse-transcriptase PCR [264]. Tissue processing is of great importance, because 
tissue exposure to RNA-denaturing conditions or agents could result in false negatives 
in EBER-ISH [308, 331]. Hence, observing good-quality yielding protocols and 
ensuring maintained cellular and molecular integrity throughout tissue processing will 
help eliminate EBER false negatives [332]. There have been reports of infrequent but 
different pattern of EBER staining in the brain by Aloisi et al [308]. Despite the 
dominance of typical nuclear EBER stain, some cells showed specific cytoplasmic 
stain in the brain, explained by EBERs release from the nuclear compartment, and this 
pattern could be a reflection of long-standing EBV infection [308]. These same factors 
are also applicable to other EBV detection techniques including IHC for EBV proteins 
and PCR amplification of EBV DNA. For IHC, tissue antigenicity should be carefully 
examined as many of the epitopes are masked in formalin fixed tissues [283] and 
recovery of immunoreactive epitopes is a matter of choosing optimal antigen retrieval 






Collectively, tissue processing, and immunostaining procedures along with selecting 
primary antibodies recognizing retrievable EBV epitopes affect results of IHC [308, 
332]. Lastly, applying PCR to detect EBV nucleic acids, as we have shown here [275], 
largely depends on isolating amplifiable quality of DNA/RNA. Also variation in 
frequency of EBV infected cells in the brain is expected, so extracting DNA/RNA 
from an area where infected cells represent a minute proportion of the whole area, 
could lead to false negative PCR results. Therefore, applying different confirmatory 
methodologies is essential to reduce the likelihood of false negatives [308, 332]. 
The study in this thesis has a number of limitations that could be summarized 
as follows: 
1- We successfully utilized long-term formalin fixed materials in exploring many 
aspects of our hypothesis. Unlike fresh samples, formalin fixed tissue is not 
optimal for many molecular studies, such as reverse-transcriptase PCR due to 
extensive degradation that takes place in the presence of formalin fixation. 
Furthermore, immunofluorescence staining of formalin fixed tissues can also lead 
to autofluorescence that makes visualizing markers of interest difficult. 
2- In our study, we only examined the presence of EBNA1 and BZLF1 as indicators 
of EBV lytic and latent infection, respectively. Using additional antibodies 
targeting other EBV antigens could help further characterize observed latent and 
lytic infection. Different latency programs could be distinguished by screening for 
presence/absence of expression of latent antigens EBNA2, LMP1 and LMP2. 
Also, different stages of EBV replicative cycle can be demonstrated by staining 






3- We focused on a few cellular marker, namely B cells, microglia and astrocytes 
marker to phenotypically characterize EBV infected cells. Testing a larger panel 
of cellular markers can be more informative for determining which cells are 
infected with EBV in MS brain. 
Based on these limitations, we think future studies should emphasize the 
biology of EBV infection in MS brain. This involves addressing questions such as 
what possible routes does the virus take to enter the brain? What events precede viral 
entry into the brain? What determines the occurrence of EBV infected cell-rich tertiary 
lymphoid structures in the brain?  Does EBV possess sufficient ability to infect cells 
other than B lymphocytes? And if that is the case, how does that disturb host-virus 
homeostasis and what is the patho-molecular pathway for interaction between different 
EBV infected cells in contributing to MS pathology? Lastly, it has been shown that 
EBV interacts with various other genetic and environmental risk factors such as HLA 
class II alleles, vitamin D receptor, smoking and HERV-W/MSRV in MS 
pathogenesis. Can future research draw a scheme of such an interaction towards MS 
pathogenesis? Will such an interaction be able to explain different pathological 
features of MS including intrathecal Ig oligoclonal bands and early axonal loss? 
In summary, in this study we hypothesized a possible contributory role of EBV 
infection in the brain in MS pathogenesis. Subsequently we presented experimental 
evidence based on several different methodologies and approaches to indicate that 
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Appendix I: Demographic and Clinical Data of MS and Control Cases 
Case Age Sex Cause of death/ remarks 
Ctrl1  55  F Extensive end-stage long-standing interstitial lung disease with 
secondary RSV infection 
Ctrl2  25 wks M Immature lung development  
Ctrl3  50  M Multifactorial: severe interstitial lung disease with honeycombing, 
cor pulmonale, 3rd degree heart block (MI) 
Ctrl4  37.5 wks M Stillborn infant: Intrauterine foetal death due to placental infarction  
Ctrl5  73  M Acute bronchopneumonia: secondary to metastatic transitional cell 
carcinoma of bladder, metastatic to the lungs, liver & vertebra 
Ctrl6  55 M Alcohol induced cirrhosis 
Ctrl7  N/A M Dementia with AD 
Ctrl8  N/A M Acute MI 
Ctrl9  N/A M MI with emphysema 
Ctrl10  N/A F Nodular sclerosing Hodgkin's  
Ctrl11  N/A M Progressive dementia with AD 
Ctrl12  69  M Respiratory distress due to acute bilateral pneumonia 
Ctrl13  38  F Massive GI haemorrhage secondary to idiopathic FHF 
Ctrl14  42  M FHF with HSV hepatitis & haemorrhagic necrosis + DIC 
Ctrl15  68 M Definite AD - slowly progressive dementia 
Ctrl16  49  F Severe intra-abdominal haemorrhage post liver biopsy, coagulopathy 
associated with chronic hepatic failure (cryptogenic cirrhosis & 
hepatitis) 
Ctrl17  50  M Multiorgan failure secondary to ischaemic cardiomyopathy (severe 
CHF) 
Ctrl18 76 M Ventricular fibrillation secondary to Ecoli septicaemia (septic shock). 
Multiple small bowel adhesions, perforations & obstructions  
Ctrl19  63 F Widely metastatic ovarian adenocarcinoma stage IIIc  
Ctrl20  74 M Dementia. Progressive supranuclear palsey-like Tauopathy  
Ctrl21  N/A N/A Meningioma 
MS1 43 M Severe chronic active & inactive MS 
MS2 74 M Moderately severe chronic inactive MS 
MS3  79 F Chronic inactive MS. Arteriosclerosis  
MS4  52 F Chronic inactive MS 
MS5  48 M Moderately severe chronic  active MS 
MS6  69 F Chronic inactive MS 
MS7  74 F Chronic inactive MS 
MS8 48 M Subacute MS: involving cervical spinal cord 
MS9  57 M Chronic inactive MS 
MS10   50 M Chronic active SPMS 
MS11  68 F Moderately severe chronic inactive MS 
MS12  61 F Mild chronic inactive 
MS13  67 F Moderately severe chronic inactive MS. >20-yr course 
MS14  80 M Severe chronic inactive MS: affecting spinal cord 
MS15   58 M Chronic active smoldering & chronic inactive 
MS16  77 F Chronic inactive SPMS: affecting spinal cord 
MS17  61 F Severe chronic inactive MS 
MS18  63 F Chronic inactive SPMS: severely affecting cervical spinal cord 
MS19  68 F Chronic inactive MS 
MS20  N/A F Multiple active & reactivated MS plaques 
MS21  81 F Moderately severe chronic inactive RRMS 






MS23  46 F Progressive MS 
MS24  77 M Moderately severe chronic inactive MS 
MS25  77 F Chronic inactive MS coexisted with AD 
MS26  78 F Moderately severe chronic inactive MS (38-yr course) 
MS27  N/A M Moderately severe chronic active MS (30-yr course) COD: PE 
MS28  41 F Chronic inactive MS 
MS29  50 M Chronic inactive MS 
MS30  70 F Chronic inactive MS 
MS31  54 M Chronic inactive MS 
MS32 87 F Chronic inactive spinal MS. Arteriolosclerosis  
MS33 70 M MS (19-yr course) 
MS34 N/A M Moderately severe chronic inactive MS. Arteriolosclerosis, cranial 
bleed 
MS35 52 M Moderately severe chronic inactive MS 
MS36 67 F Progressive MS 
MS37 54 F Severe chronic inactive MS (25-yr course) 
MS38 69 F Chronic inactive MS  
MS39 75 F Chronic inactive MS: affecting spinal cord. COD: respiratory failure 
MS40 58 F Chronic inactive MS (20 yr course). Atherosclerosis, arteriosclerosis 
MS41 60 F Chronic inactive MS 
MS42 53 F Moderately severe chronic inactive MS 
MS43 50 F Moderately severe chronic inactive MS 
MS44 65 F Very minimal demyelinative MS plaque burden 
MS45 92 F Moderate chronic inactive MS. Arteriolosclerosis  
MS46 59 M Moderately severe chronic inactive MS.  Atherosclerosis  
MS47 59 M MS- no further information available 
MS48  43 M Chronic inactive with chronic active smoldering MS 
MS49  59 M Chronic inactive MS 
MS50  53 F MS- no further information available 
MS51  56 F Severe chronic inactive PPMS, (40-yr course). Idiopathic  
Parkinsonism 
MS52  29 F MS- no further information available 
MS53  76 F MS- no further information available 
MS54  42 M MS- no further information available 
MS55  67 M MS- no further information available 
MS56  65 F MS- no further information available 
MS57  42 M MS- no further information available 
MS58  98 M MS- no further information available 
MS59  77 F MS- no further information available 
MS60  79 M MS- no further information available 
MS61  66 M MS- no further information available 
MS62  70 F MS- no further information available 
MS63  32 F Chronic inactive noninflammatory RRMS, PML 
MS64   F MS- no further information available 
MS65  60 F MS- no further information available 
MS66  57 F Chronic active MS 
MS67  70 M MS- no further information available 
MS68  56 F MS- no further information available 
MS69  75 F MS- no further information available 
MS70  71 F MS- no further information available 
MS71  45 M Severe spinal mixed chronic inactive & active MS (10-yr). PML 
MS72 57 F MS- no further information available 
MS73  66 F MS- no further information available 
MS74  75 M MS- no further information available 
MS75  59 M Moderately severe chronic active MS 
MS76  60 F MS- no further information available 
MS77  61 F MS- no further information available 






MS79  61 F Severe chronic active smoldering MS 
MS80  84 F MS- no further information available 
MS81  71 F MS- no further information available 
MS82  71 F MS- no further information available 
MS83  61 M MS- no further information available 
MS84  62 M MS- no further information available 
MS85  63 F Chronic inactive SPMS 
MS86  74 F Chronic inactive MS 
MS87  65 F MS- no further information available 
MS88  89 F MS- no further information available 
MS89  70 M MS- no further information available 
MS90  46 F MS- no further information available 
MS91  59 F MS- no further information available 
MS92  69 F MS- no further information available 
MS93  70 F MS- no further information available 
MS94   F MS- no further information available 
MS95  64 F MS- no further information available 
MS96  60 F MS- no further information available 
MS97  56 M MS- no further information available 
MS98  67 F MS- no further information available 
MS99  67 F MS- no further information available 
MS100 74 F Chronic inactive SPMS with superimposed relapses 
MS101 77 F MS- no further information available 
 
Appendix II: Buffers and reagents preparation 
A- Preparation of hybridization buffer 
      Five millilitre hybridization buffer was prepared by mixing: 
1- 2.5ml formamide deionized (Sigma Cat# F9037),  
2- 1ml 25% dextran sulphate (Sigma Cat# D8906),  
3- 500µl 20x SSC (saline sodium citrate, pH7.0. 1L: 175.3g NaCl (3 M) + 88.2g 
sodium citrate + 800mL sterile dH2O), 
4- 125µl 2M Tris-HCl pH 7.5,  
5- 875µl ddH2O.   
 
B- Preparation of 10xPBS (phosphate buffered saline): 
 10x in 1L ddH2O: 80g NaCl, 2g KCl, 14.4g Na2HPO4, 2.4g KH2PO4; pH 7.4. 
 
C- Preparation of DAB:  
One gram of DAB powder was dissolved in 40 ml water with ~5 drops of HCl 







Appendix III: Coating slides 
D- Coating histology slides: 
1- Slides were washed in water for 30 minutes 
2- Slides were immersed in acetone (Panreac, 361007) for 5 minutes 
3- Slides were incubated in 2% 3-aminpropyltriethoxysilane in acetone for  
another 5 minutes 
4- Slides were rinsed in distilled water for a minute and eventually left to air 
dry overnight 
 
 
 
